<SEC-DOCUMENT>0001047469-20-003564.txt : 20200612
<SEC-HEADER>0001047469-20-003564.hdr.sgml : 20200612
<ACCEPTANCE-DATETIME>20200612152326
ACCESSION NUMBER:		0001047469-20-003564
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20200612
DATE AS OF CHANGE:		20200612

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Celldex Therapeutics, Inc.
		CENTRAL INDEX KEY:			0000744218
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				133191702
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-235399
		FILM NUMBER:		20960035

	BUSINESS ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827
		BUSINESS PHONE:		908-200-7500

	MAIL ADDRESS:	
		STREET 1:		53 FRONTAGE ROAD
		STREET 2:		SUITE 220
		CITY:			HAMPTON
		STATE:			NJ
		ZIP:			08827

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AVANT IMMUNOTHERAPEUTICS INC
		DATE OF NAME CHANGE:	19980828

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	T CELL SCIENCES INC
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>a2241865z424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML>
<HEAD>
</HEAD>
<BODY BGCOLOR="#FFFFFF" LINK=BLUE  VLINK=PURPLE>
<BR>
<P><FONT SIZE=3 >
Use these links to rapidly review the document<BR>
<A HREF="#bg40303_table_of_contents">  TABLE OF CONTENTS</A> <BR>
<A HREF="#bg40304_table_of_contents">  TABLE OF CONTENTS</A><BR></font>
</P>

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg40303a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><B>Filed Pursuant to Rule&nbsp;424(b)(5)<BR>
Registration No.&nbsp;333- 235399  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> PROSPECTUS SUPPLEMENT<BR>
(To Prospectus Dated June&nbsp;12, 2020)  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g985367.jpg" ALT="LOGO" WIDTH="171" HEIGHT="42">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>Up to $75,000,000<BR>
Common Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In accordance with the terms of the Controlled Equity Offering<SUP>SM</SUP> sales agreement, dated May&nbsp;19, 2016, we entered into with
Cantor Fitzgerald&nbsp;&amp;&nbsp;Co., or Cantor Fitzgerald, we may offer and sell shares of our common stock having an aggregate offering price of up to an additional $75.0&nbsp;million from time
to time through Cantor Fitzgerald, acting as sales agent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
common stock is traded on the Nasdaq Capital Market, or Nasdaq, under the symbol "CLDX". On June&nbsp;11, 2020 the last reported sales price of our common stock on Nasdaq was $8.76
per share. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales
of our common stock, if any, under this prospectus supplement and the accompanying prospectus may be made in sales deemed to be an "at the market offering" as defined in
Rule&nbsp;415(a)(4) promulgated under the Securities Act of 1933, as amended, or the Securities Act, including sales made directly on or through Nasdaq or any other existing trading market for our
common stock. Cantor Fitzgerald is not required to sell any specific number or dollar amount of securities, but will act as a sales agent using commercially reasonable efforts consistent with its
normal trading and sales practices, on mutually agreed terms between Cantor Fitzgerald and us. There is no arrangement for funds to be received in any escrow, trust or similar arrangement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cantor
Fitzgerald will be entitled to compensation at a fixed commission rate equal to 3.0% of the gross sales price per share sold. In connection with the sale of our common stock on
our behalf, Cantor Fitzgerald will be deemed to be an "underwriter" within the meaning of the Securities Act and the compensation of Cantor Fitzgerald will be deemed to be underwriting commissions or
discounts. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=3><B>Investing in our common stock involves risks. Before buying any shares, you should read the discussion of material risks of investing in our
common stock in "Risk Factors" beginning on page&nbsp;S-5 of this prospectus supplement, and in the risks discussed under similar headings in the documents incorporated by reference in this
prospectus supplement and accompanying prospectus, as they may be amended,
updated or modified periodically in our reports filed with the Securities and Exchange Commission.</B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these
securities or determined if this prospectus supplement and accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g561532.jpg" ALT="LOGO" WIDTH="231" HEIGHT="43">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>The date of this prospectus supplement is June&nbsp;12, 2020.  </B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=1,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=294463,FOLIO='blank',FILE='DISK133:[20ZCT3.20ZCT40303]BE40303A.;9',USER='JTAYLORA',CD='12-JUN-2020;13:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40303a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="BG40303A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bg40303_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG40303_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="27pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH COLSPAN=2 ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Prospectus Supplement</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da40303_about_this_prospectus_supplement"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ABOUT THIS PROSPECTUS SUPPLEMENT</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da40303_about_this_prospectus_supplement"><FONT SIZE=2>S-1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc40303_prospectus_supplement_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROSPECTUS SUPPLEMENT SUMMARY</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc40303_prospectus_supplement_summary"><FONT SIZE=2>S-2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dg40303_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dg40303_risk_factors"><FONT SIZE=2>S-5</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di40303_special_note_regarding_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di40303_special_note_regarding_forward-looking_statements"><FONT SIZE=2>S-7</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di40303_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di40303_use_of_proceeds"><FONT SIZE=2>S-9</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PRICE RANGE OF OUR COMMON STOCK</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#di40303_dilution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DILUTION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#di40303_dilution"><FONT SIZE=2>S-10</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk40303_plan_of_distribution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PLAN OF DISTRIBUTION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk40303_plan_of_distribution"><FONT SIZE=2>S-11</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk40303_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk40303_legal_matters"><FONT SIZE=2>S-12</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk40303_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk40303_experts"><FONT SIZE=2>S-12</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk40303_where_you_can_find_more_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk40303_where_you_can_find_more_information"><FONT SIZE=2>S-12</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dk40303_incorporation_of_documents_by_reference"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION OF DOCUMENTS BY REFERENCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dk40303_incorporation_of_documents_by_reference"><FONT SIZE=2>S-12</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Prospectus</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2><BR>
&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#bi40304_about_this_prospectus"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ABOUT THIS PROSPECTUS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#bi40304_about_this_prospectus"><FONT SIZE=2>1</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#ca40304_prospectus_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROSPECTUS SUMMARY</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#ca40304_prospectus_summary"><FONT SIZE=2>2</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da40304_special_note_regarding_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da40304_special_note_regarding_forward-looking_statements"><FONT SIZE=2>3</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da40304_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da40304_risk_factors"><FONT SIZE=2>3</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RATIOS OF COMBINED FIXED CHARGES AND PREFERRED STOCK DIVIDENDS TO EARNINGS</FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da40304_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da40304_use_of_proceeds"><FONT SIZE=2>4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da40304_descriptions_of_securities_we_may_offer"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTIONS OF SECURITIES WE MAY OFFER</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da40304_descriptions_of_securities_we_may_offer"><FONT SIZE=2>4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da40304_description_of_common_stock"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF COMMON STOCK</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da40304_description_of_common_stock"><FONT SIZE=2>4</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da40304_description_of_preferred_stock"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF PREFERRED STOCK</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da40304_description_of_preferred_stock"><FONT SIZE=2>5</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#da40304_description_of_warrants"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF WARRANTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#da40304_description_of_warrants"><FONT SIZE=2>8</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc40304_description_of_depositary_shares"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF DEPOSITARY SHARES</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc40304_description_of_depositary_shares"><FONT SIZE=2>10</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc40304_description_of_units"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF UNITS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc40304_description_of_units"><FONT SIZE=2>10</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc40304_plan_of_distribution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PLAN OF DISTRIBUTION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc40304_plan_of_distribution"><FONT SIZE=2>11</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc40304_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc40304_legal_matters"><FONT SIZE=2>13</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc40304_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc40304_experts"><FONT SIZE=2>13</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc40304_where_you_can_find_more_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc40304_where_you_can_find_more_information"><FONT SIZE=2>13</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><A HREF="#dc40304_incorporation_of_certain_documents_by_reference"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><A HREF="#dc40304_incorporation_of_certain_documents_by_reference"><FONT SIZE=2>13</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=2,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=65797,FOLIO='blank',FILE='DISK133:[20ZCT3.20ZCT40303]BG40303A.;8',USER='JTAYLORA',CD='12-JUN-2020;13:07' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_da40303_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40303a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da40303_about_this_prospectus_supplement"> </A>
<A NAME="toc_da40303_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THIS PROSPECTUS SUPPLEMENT    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In this prospectus supplement, "Celldex," "we," "us," "our" or "ours" refer to Celldex Therapeutics,&nbsp;Inc. and its consolidated
subsidiary. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus supplement and the accompanying prospectus relate to the offering of shares of our common stock. Before buying any of the shares of common stock offered hereby, we urge
you to carefully read this prospectus supplement and the accompanying prospectus, together with the information incorporated herein by reference as described under the headings "Where You Can Find
More Information" and "Incorporation of Documents by Reference." These documents contain important information that you should consider when making your investment decision. This prospectus supplement
contains information about the common stock offered hereby and may add, update or change information in the accompanying prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should rely only on the information that we have provided or incorporated by reference in this prospectus supplement and the accompanying prospectus. We have not, and Cantor
Fitzgerald has not, authorized any other person to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are not, and Cantor Fitzgerald is not, making offers to sell or solicitations to buy our common stock in any jurisdiction in which an offer or solicitation is not authorized or in
which the person making that offer or solicitation is not qualified to do so or to anyone to whom it is unlawful to make an offer or solicitation. You should assume that the information in this
prospectus supplement and the accompanying prospectus or any related free writing prospectus is accurate only as of the date on the front of the document and that any information that we have
incorporated by reference is accurate only as of the date of the document incorporated by reference, regardless of the time of delivery of this prospectus supplement, the accompanying prospectus or
any related free writing prospectus, or any sale of a security. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
document is in two parts. The first part is this prospectus supplement, which adds to and updates information contained in the accompanying prospectus. The second part, the
prospectus, provides more general information, some of which may not apply to this offering. Generally, when we refer to this prospectus, we are referring to both parts of this document combined. To
the extent there is a conflict between the information contained in this prospectus supplement and the information contained in the accompanying prospectus, you should rely on the information in this
prospectus supplement. However, if any statement in one of these documents is inconsistent with a statement in another document having a later date&#151;for example, a document incorporated by
reference into this prospectus supplement&#151;the statement in the document having the later date modifies or supersedes the earlier statement as our business, financial condition, results of
operations and prospects may have changed since the earlier dates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus supplement and the accompanying prospectus contain summaries of certain provisions contained in some of the documents described herein, but reference is made to the
actual documents for complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred to herein have been or will be filed
as exhibits to the registration statement of which this prospectus is a part or as exhibits to documents incorporated by reference herein, and you may obtain copies of those documents as described
below under the headings "Where You Can Find More Information" and "Incorporation of Documents by Reference." </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;"Celldex
Therapeutics" and our design logo used in this prospectus supplement and the accompanying prospectus are our trademarks. This prospectus supplement and the accompanying
prospectus may also include other trademarks, tradenames and service marks that are the property of their respective holders. Solely for convenience, trademarks and tradenames referred to in this
prospectus supplement and the accompanying prospectus may appear without the &reg; and &#153; symbols, but those references are not intended to indicate, in any way, that we will not
assert, to the fullest extent under applicable law, our rights, or that the applicable holder will not assert its rights, to these trademarks and tradenames. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=3,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=480684,FOLIO='S-1',FILE='DISK133:[20ZCT3.20ZCT40303]DA40303A.;4',USER='JTAYLORA',CD='12-JUN-2020;13:07' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dc40303_1_2"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40303a_main_toc">Table of Contents</A> </FONT></P>


<P style="font-family:times;"><FONT SIZE=2><BR></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc40303_prospectus_supplement_summary"> </A>
<A NAME="toc_dc40303_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUPPLEMENT SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>The following summary of our business highlights some of the information contained elsewhere in or incorporated by
reference into this prospectus supplement. Because this is only a summary, however, it does not contain all of the information that may be important to you. You should carefully read this prospectus
supplement and the accompanying prospectus, including the documents incorporated by reference, which are described under "Incorporation of Documents by Reference" and "Where You Can Find More
Information" in this prospectus supplement. You should also carefully consider the matters discussed in the section titled "Risk Factors" in this prospectus supplement and in the accompanying
prospectus and in other periodic reports incorporated by reference herein.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Our Company  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a biopharmaceutical company focused on the development and commercialization of immunotherapies and other targeted biologics. Our drug
candidates are derived from a broad set of human and bispecific antibodies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or
other diseases. They are aimed at addressing market opportunities for which we believe current therapies are inadequate or non-existent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are focusing our efforts and resources on the continued research and development of:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> CDX-0159, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which recently completed a
Phase&nbsp;1a study in healthy volunteers where it demonstrated a favorable safety profile as well as profound and durable reductions of plasma tryptase, consistent with systemic mast cell
suppression. We plan to study CDX-0159 in mast cell driven diseases, including, initially, chronic spontaneous urticaria (CSU) and chronic inducible urticarias (CINDUs); </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> CDX-1140, an agonist monoclonal antibody targeted to CD40, a key activator of immune response, currently being studied as a single-agent and in
combination with CDX-301, a dendritic cell growth factor. Dose escalation was recently completed in a Phase&nbsp;1 study in solid tumors and lymphoma and the recommended dose for further study was
determined to be 1.5 mg/kg, one of the highest systemic dose levels in the CD40 agonist class, for both CDX-1140 monotherapy and in combination with dose levels in the CD40 agonist class, for both
CDX-1140 monotherapy and in combination with CDX-301. Celldex has initiated multiple expansion cohorts within the study, including a combination cohort with KEYTRUDA&reg; (pembrolizumab). The
Company is exploring additional combination cohorts with mechanisms that we believe could be complementary or synergistic with CDX-1140; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> CDX-3379, a monoclonal antibody designed to block the activity of ErbB3 (HER3), currently in an early Phase&nbsp;2 study in advanced head and
neck squamous cell cancer in combination with Erbitux&reg;<SUP>;</SUP> and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> CDX-527, a bispecific antibody that uses our proprietary highly active anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with
blockade of the PD-L1/PD-1 pathway, for which we are planning a Phase&nbsp;1 study in advanced solid tumors. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
routinely work with external parties to collaboratively advance our drug candidates. In addition to Celldex-led studies, we also have an Investigator Initiated Research (IIR) program
with multiple studies ongoing with our drug candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for patients with unmet medical needs. We believe our program assets
provide us with the strategic options to either retain full economic rights to our innovative therapies or seek favorable economic terms through advantageous commercial partnerships. This approach
allows us to </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=4,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=116621,FOLIO='S-2',FILE='DISK133:[20ZCT3.20ZCT40303]DC40303A.;5',USER='JTAYLORA',CD='12-JUN-2020;13:08' -->
<A NAME="page_dc40303_1_3"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40303a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">


<P style="font-family:times;"><FONT SIZE=2>maximize
the overall value of our technology and product portfolio while best ensuring the expeditious development of each individual product. Currently, all programs are fully owned by Celldex. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a Delaware corporation organized in 1983. Our principal executive offices are located at Perryville III Building, 53 Frontage Road,
Suite&nbsp;220, Hampton, New Jersey 08827 and our telephone number is (908)&nbsp;200-7500. Our corporate website is www.celldex.com. The information on our website is not incorporated by reference
into this prospectus. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=5,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=708013,FOLIO='S-3',FILE='DISK133:[20ZCT3.20ZCT40303]DC40303A.;5',USER='JTAYLORA',CD='12-JUN-2020;13:08' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_de40303_1_4"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40303a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="de40303_the_offering"> </A>
<A NAME="toc_de40303_1"> </A>
<BR></FONT><FONT SIZE=2><B>  THE OFFERING    <BR>    </B></FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="218pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Common stock offered by us</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><FONT SIZE=2>Shares of our common stock having an aggregate offering price of up to $75.0&nbsp;million.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Common stock to be outstanding after this offering</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Up to 29,236,912 shares, assuming sales at a price of $8.76 per share, which was the closing price of our common stock on
Nasdaq on June&nbsp;11, 2020. The actual number of shares issued will vary depending on the sales price under this offering.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Plan of Distribution</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>"At the market offering" that may be made from time to time through our sales agent, Cantor Fitzgerald. See "Plan of
Distribution" beginning on page&nbsp;S-11 of this prospectus supplement.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Use of Proceeds</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>We currently intend to use the net proceeds from this offering, if any, for working capital and other general corporate
purposes. See "Use of Proceeds" on page&nbsp;S-9 of this prospectus supplement.</FONT></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>Risk Factors</B></FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD VALIGN="BOTTOM" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Investing in our common stock involves a high degree of risk. See "Risk Factors" beginning on page&nbsp;S-5 of this
prospectus supplement and under similar headings in the other documents that are filed after the date hereof and incorporated by reference in this prospectus supplement for a discussion of factors to consider before deciding to purchase shares of our
common stock.</FONT></TD>
</TR>
<TR VALIGN="BOTTOM">
<TD VALIGN="TOP" style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2><B>The Nasdaq Global Market symbol</B></FONT></TD>
<TD VALIGN="TOP" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><p style="font-family:times;margin-top:12pt;margin-left:0pt;text-indent:0pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>"CLDX"</FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
total number of shares of common stock to be outstanding immediately after this offering is based on 20,675,269 shares of common stock issued and outstanding as of June&nbsp;10,
2020, which does not include the following, all as of March&nbsp;31, 2020:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 1,658,141 shares issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $44.65 per share; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 465,324 shares reserved for future issuance under our equity compensation plans. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless
otherwise stated, all information in this prospectus supplement:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> assumes no exercise of outstanding options to purchase common stock and no issuance of shares available for future issuance under our equity
compensation plans; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> reflects all currency in U.S. dollars. </FONT></DD></DL>
</UL>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=6,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=346581,FOLIO='S-4',FILE='DISK133:[20ZCT3.20ZCT40303]DE40303A.;8',USER='JTAYLORA',CD='12-JUN-2020;13:08' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dg40303_1_5"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40303a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dg40303_risk_factors"> </A>
<A NAME="toc_dg40303_1"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>An investment in our securities involves a high degree of risk. You should carefully consider the risks described under
"Risk Factors" in the accompanying prospectus and our <A HREF="http://www.sec.gov/Archives/edgar/data/744218/000104746920001809/a2241053z10-k.htm">Annual Report on Form&nbsp;10-K for the
year ended December&nbsp;31, 2019</A>, respectively, as updated by any other document that we subsequently file with the Securities and Exchange Commission and that is incorporated by
reference into this prospectus supplement and the accompanying prospectus, as well as the risks described below and all of the other information contained in this prospectus supplement and the
accompanying prospectus, and incorporated by reference into this prospectus supplement and the accompanying prospectus, including our financial statements and related notes, before investing in our
securities. These risks and uncertainties are not the only ones facing us, and there may be additional matters that we are unaware of or that we currently consider immaterial. All of these could
adversely affect our business, business prospects, cash flow, results of operations and financial condition. In such case, the trading price of our common stock could decline, and you could lose all
or part of your investment in our common stock.</I></FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Risks Related to this Offering  </B></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Management will have broad discretion as to the use of the proceeds from this offering, and we may not use
the proceeds effectively.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because we have not designated the amount of net proceeds received by us from this offering to be used for any particular purpose, our
management will have broad discretion as to the application of the net proceeds from this offering and could use them for purposes other than those contemplated at the time of the offering. Our
management may use the net proceeds for corporate purposes that may not improve our financial condition or market value. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


If you purchase shares of common stock sold in this offering, you will experience immediate and substantial
dilution in the book value per share of the common stock you purchase.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Because the price per share of our common stock being offered may be higher than the book value per share of our common stock, you may suffer
substantial dilution in the net tangible book value of the common stock you purchase in this offering. See the section entitled "Dilution" below for a more detailed discussion of the dilution you will
incur if you purchase common stock in this offering. In addition, we have a significant number of options and restricted stock outstanding. If the holders of these securities exercise them or become
vested in them, as applicable, you may incur further dilution. </FONT></P>


<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


You may experience future dilution as a result of future equity offerings or if we elect to pay milestones,
if any, due to former Kolltan holders in shares of our common stock.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;To raise additional capital, we may in the future offer additional shares of our common stock or other securities convertible into or
exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any other offering at a price per share that is
less than the price per share paid by investors in this
offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. The price per share at which we sell additional shares of our common
stock, or securities convertible or exchangeable into common stock, in future transactions may be higher or lower than the price per share paid by investors in this offering. In addition, in the event
that certain specified preclinical and clinical development milestones related to Kolltan's development programs and/or Celldex's development programs and certain commercial milestones related to
Kolltan's drug candidates are achieved, we will be required to pay Kolltan's stockholders milestone payments of up to $172.5&nbsp;million, which milestone payments may be made, at our sole election,
in cash, in shares of our common stock or a combination of both, subject to provisions of the merger agreement. If we elect to issue shares of our common stock, you will experience further dilution. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=7,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=73885,FOLIO='S-5',FILE='DISK133:[20ZCT3.20ZCT40303]DG40303A.;7',USER='JTAYLORA',CD='12-JUN-2020;13:06' -->
<A NAME="page_dg40303_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40303a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Sales of a significant number of shares of our common stock in the public markets, or the perception that
such sales could occur, which sales may occur during or immediately after sales pursuant to this offering are commenced, could depress the market price of our common stock.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Sales of a substantial number of shares of our common stock in the public markets, or the perception that such sales could occur, could depress
the market price of our common stock and impair our ability to raise capital through the sale of additional equity securities. We have agreed, without the prior written consent of Cantor Fitzgerald.
and subject to certain exceptions set forth in the sales agreement, not to sell or otherwise dispose of any common stock or securities convertible into or exchangeable for shares of common stock,
warrants or any rights to purchase or acquire common stock during the period beginning on the fifth trading day immediately prior to the delivery of any placement notice delivered by us to Cantor
Fitzgerald and ending on the fifth trading day immediately following the final settlement date with respect to the shares sold pursuant to such notice. We have further agreed, subject to certain
exceptions set forth in the sales agreement, not to sell or otherwise dispose of any common stock or securities convertible into or exchangeable for shares of common stock, warrants or any rights to
purchase or acquire common stock in any other "at-the-market" or continuous equity transaction prior to the termination of the sales agreement with Cantor Fitzgerald. Therefore, at any time, including
during the pendency of this offering, it is possible that we could issue and sell additional shares of our common stock in the public markets other than pursuant to this offering, including, without
limitation, through underwritten public offerings, privately negotiated transactions, block trades, or any combination of the above, subject, in certain circumstances, to the consent of Cantor
Fitzgerald. We cannot predict the effect that future sales of our common stock would have on the market price of our common stock. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Our share price has been and could remain volatile.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The market price of our common stock has historically experienced and may continue to experience significant volatility. From January 2018
through June&nbsp;11, 2020, the market price of our common stock has fluctuated from a high of $46.20 per share in the first quarter of 2018, to a low of $1.50 per share in the first quarter of
2020. Our progress in developing and commercializing our products, the impact of government regulations on our products and industry, the potential sale of a large volume of our common stock by
stockholders, our quarterly operating results, changes in general conditions in the economy or the financial markets and other developments affecting us or our competitors could cause the market price
of our common stock to fluctuate substantially with significant market losses. If our stockholders sell a substantial number of shares of common stock, especially if those sales are made during a
short period of time, those sales could adversely affect the market price of our common stock and could impair our ability to raise capital. In addition, in recent years, the stock market has
experienced significant price and volume fluctuations. This volatility has affected the market prices of securities issued by many companies for reasons unrelated to their operating performance and
may adversely affect the price of our common stock. In addition, we could be subject to a securities class action litigation as a result of volatility in the price of our stock, which could result in
substantial costs and diversion of management's attention and resources and could harm our stock price, business, prospects, results of operations and financial condition. </FONT></P>

<P style="font-family:times;;margin-left:0pt;text-indent:-0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:0pt;text-indent:-0pt;" -->


Because we do not intend to declare cash dividends on our shares of common stock in the foreseeable future,
stockholders must rely on appreciation of the value of our common stock for any return on their investment.  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have never declared or paid cash dividends on our common stock. We currently anticipate that we will retain future earnings for the
development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends in the foreseeable future. In addition, the terms of any existing or future debt
agreements may preclude us from paying dividends. As a result, we expect that only appreciation of the price of our common stock, if any, will provide a return to investors in this offering for the
foreseeable future. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=8,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=156742,FOLIO='S-6',FILE='DISK133:[20ZCT3.20ZCT40303]DG40303A.;7',USER='JTAYLORA',CD='12-JUN-2020;13:06' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_di40303_1_7"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40303a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="di40303_special_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_di40303_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein contain forward-looking statements
made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements represent our management's judgment regarding future events. In many
cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "plan," "expect," "anticipate," "estimate," "predict," "intend," "potential" or "continue" or the
negative of these terms or other words of similar import, although some forward-looking statements are expressed differently. All statements other than statements of historical fact included in this
prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein regarding our financial position, business strategy and plans or objectives for future operations
are forward-looking statements. Without limiting the broader description of forward-looking statements above, we specifically note that statements regarding potential drug candidates, their potential
therapeutic effect, the possibility of obtaining regulatory approval, our expected timing for completing clinical trials and clinical trial milestones for our drug candidates, our ability or the
ability of our collaborators to manufacture and
sell any products, market acceptance or our ability to earn a profit from sales or licenses of any drug candidate or to discover new drugs in the future are all forward-looking in nature. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;There
are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include,
but are not limited to:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to successfully complete research and further development, including animal, preclinical and clinical studies, and, if we obtain
regulatory approval, commercialization of our drug candidates and the growth of the markets for those drug candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to raise sufficient capital to fund our animal, preclinical and clinical studies and to meet our liquidity needs, on terms
acceptable to us, or at all. If we are unable to raise the funds necessary to meet our liquidity needs, we may have to delay or discontinue the development of one or more programs, discontinue or
delay ongoing or anticipated clinical trials, license out programs earlier than expected, raise funds at significant discount or on other unfavorable terms, if at all, or sell all or part of our
business; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to continue as a going concern; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our anticipated timing for preclinical development, regulatory submissions, commencement and completion of clinical trials and product
approvals; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the impact of the recent outbreak of a novel strain of coronavirus ("COVID-19") on our business or on the economy generally; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the recent coronavirus outbreak will affect the timing of the completion of our planned and/or currently ongoing preclinical/clinical
trials; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to negotiate strategic partnerships, where appropriate, for our drug candidates; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to manage multiple clinical trials for a variety of drug candidates at different stages of development; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost, timing, scope and results of ongoing preclinical and clinical testing; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our expectations of the attributes of our product and development candidates, including pharmaceutical properties, efficacy, safety and dosing
regimens; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost, timing and uncertainty of obtaining regulatory approvals for our drug candidates; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=9,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=466853,FOLIO='S-7',FILE='DISK133:[20ZCT3.20ZCT40303]DI40303A.;5',USER='JTAYLORA',CD='12-JUN-2020;13:08' -->
<A NAME="page_di40303_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40303a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the availability, cost, delivery and quality of clinical management services provided by our clinical research organization partners; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the availability, cost, delivery and quality of clinical and commercial-grade materials produced by our own manufacturing facility or supplied
by contract manufacturers, suppliers and partners; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to develop technological capabilities, including identification of novel and clinically important targets, exploiting our existing
technology platforms to develop new drug candidates and expand our focus to broader markets for our existing targeted immunotherapeutics; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to develop and commercialize products before competitors that are superior to the alternatives developed by such competitors; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the cost of paying development, regulatory approval and sales-based milestones under the merger agreement by which we acquired Kolltan,
including under any future amendment to that agreement; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to realize the anticipated benefits from the acquisition of Kolltan; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to protect our intellectual property rights and our ability to avoid intellectual property litigation, which can be costly and
divert management time and attention; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our ability to develop and commercialize products without infringing the intellectual property rights of third parties; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the risk factors set forth elsewhere in this quarterly report on Form&nbsp;10-Q and the factors listed under the headings "Business," "Risk
Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's annual report on Form&nbsp;10-K for the year ended December&nbsp;31, 2019 and
other reports that we file with the Securities and Exchange Commission. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should also consider carefully the statements set forth in the section entitled "Risk Factors" in this prospectus supplement and in our
<A HREF="http://www.sec.gov/Archives/edgar/data/744218/000104746920001809/a2241053z10-k.htm">Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2019</A>,
respectively, as updated by any other document that we subsequently filed with the Securities and Exchange Commission and that is incorporated by reference into this prospectus supplement, which
address various factors that could cause results or events to differ from those described in the forward-looking statements. All subsequent written and oral forward-looking statements attributable to
us or to persons acting on our behalf are expressly qualified in their entirety by the applicable cautionary statements. We have no plans to update these forward-looking statements. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=10,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=819802,FOLIO='S-8',FILE='DISK133:[20ZCT3.20ZCT40303]DI40303A.;5',USER='JTAYLORA',CD='12-JUN-2020;13:08' -->
<A NAME="page_di40303_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40303a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="di40303_use_of_proceeds"> </A>
<A NAME="toc_di40303_2"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The amount of proceeds from this offering will depend upon the number of shares of our common stock sold and the market price at which they are
sold. There can be no assurance that we will be able to sell any shares under or fully utilize the sales agreement with Cantor Fitzgerald as a source of financing. We currently expect to use the net
proceeds from this offering for working capital and other general corporate purposes. Until we use the net proceeds of this offering, we intend to invest the funds in short-term, investment grade,
interest-bearing securities. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
amount and timing of actual expenditures for the purposes set forth above may vary based on several factors, and our management will retain broad discretion as to the ultimate
allocation of the proceeds. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=11,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=726237,FOLIO='S-9',FILE='DISK133:[20ZCT3.20ZCT40303]DI40303A.;5',USER='JTAYLORA',CD='12-JUN-2020;13:08' -->
<A NAME="page_di40303_1_10"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40303a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="di40303_dilution"> </A>
<A NAME="toc_di40303_3"> </A>
<BR></FONT><FONT SIZE=2><B>  DILUTION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If you invest in our common stock in this offering, your ownership interest will be diluted to the extent of the difference between the price
per share you pay in this offering and our pro forma net tangible book value per share after this offering. We calculate net tangible book value per share by dividing our net tangible book value,
which is tangible assets less total liabilities, by the number of outstanding shares of our common stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
net tangible book value as of March&nbsp;31, 2020 was approximately $35.0&nbsp;million or $1.97 per share. Net tangible book value per share after this offering gives effect to
the sale of $75.0&nbsp;million of common stock in this offering at an assumed offering price of $8.76 per share, which was the closing price of our common stock as reported on Nasdaq on
June&nbsp;11, 2020, after deducting offering commissions and estimated expenses payable by us. Our net tangible book value as of March&nbsp;31, 2020, after giving effect to this offering as
described above, would have been approximately $107.7&nbsp;million, or $4.09 per share of common stock. This represents an immediate increase in pro forma net tangible book value of $2.12 per share
to existing stockholders and an immediate dilution of $4.67 per share to new investors purchasing our common stock in this offering. The following table illustrates the per share dilution: </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:70%;margin-left:15%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="7pt" ALIGN="RIGHT" style="font-family:times;"></TD>
<TD WIDTH="32pt" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Assumed public offering price per share</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>8.76</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Net tangible book value per share as of March&nbsp;31, 2020</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>1.97</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:20pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Increase in net tangible book value per share attributable to this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>2.12</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="White" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Pro forma net tangible book value per share as of March&nbsp;31, 2020, after giving effect to this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.09 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR BGCOLOR="#CCEEFF" VALIGN="BOTTOM">
<TD style="font-family:times;"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>Dilution per share to investors participating in this offering</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>
<!-- -->
$</FONT></TD>
<TD ALIGN="RIGHT" style="font-family:times;"><FONT SIZE=2>4.67 </FONT></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->





<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;</TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>

<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0.75pt;font-size:0.75pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0.75pt;font-size:0.75pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
</TR>
<TR bgcolor="#FFFFFF"  VALIGN="BOTTOM">
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2>


<!-- COMMAND=ADD_ROWSHADECOLOR,"#FFFFFF" -->




<!-- COMMAND=ADD_GUTTERGRID,"line-height:0pt;font-size:1.5pt;" -->


 </font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD ALIGN="RIGHT" style="line-height:0pt;font-size:1.5pt;font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=2></font>&#8203;


<!-- COMMAND=ADD_GRID,"border-bottom:solid #000000 1.0pt;" -->


 <font></FONT></TD>
<TD style="line-height:0pt;font-size:1.5pt;font-family:times;"><FONT SIZE=2></font>&#8203;<font> </FONT></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
 </DIV>
 <P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
above table is based on 17,730,802 shares of our common stock issued and outstanding as of March&nbsp;31, 2020, which does not include approximately 2,944,467 shares issued after
March&nbsp;31, 2020 and the following:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 1,658,141 shares issuable upon the exercise of outstanding stock options with a weighted-average exercise price of $44.65 per share; and </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> 465,324 shares reserved for future issuance under our equity compensation plans. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=12,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=772806,FOLIO='S-10',FILE='DISK133:[20ZCT3.20ZCT40303]DI40303A.;5',USER='JTAYLORA',CD='12-JUN-2020;13:08' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dk40303_1_11"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40303a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dk40303_plan_of_distribution"> </A>
<A NAME="toc_dk40303_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PLAN OF DISTRIBUTION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On May&nbsp;19, 2016, we entered into a Controlled Equity Offering<SUP>SM</SUP> sales agreement with Cantor Fitzgerald&nbsp;&amp;&nbsp;Co.,
or Cantor, under which we issued and sold shares of our common stock having an aggregate gross sales price of approximately $60.0&nbsp;million under the sales agreement prospectus dated
May&nbsp;19, 2016. Pursuant to a prospectus supplement dated November&nbsp;9, 2017, we sold additional shares of common stock having an aggregate gross sales price of $75&nbsp;million. Pursuant
to this prospectus supplement, we may offer and sell an additional $75.0&nbsp;million in aggregate gross sales price of our common stock from time to time through Cantor acting as agent pursuant to
the sales agreement. This summary of the material provisions of the sales agreement does not purport to be a complete statement of its terms and conditions. A copy of the sales agreement is filed with
the SEC and is incorporated by reference into the registration statement of which this prospectus supplement is a part. See "Where You Can Find More Information" below. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
delivery of a placement notice and subject to the terms and conditions of the sales agreement, Cantor may sell our common stock by any method permitted by law deemed to be an "at
the market offering" as defined in Rule&nbsp;415(a)(4) promulgated under the Securities Act, including sales made directly on Nasdaq or any other existing trading market for our common stock. We or
Cantor may suspend or terminate the offering of our common stock upon notice and subject to other conditions. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will pay Cantor in cash, upon each sale of our common stock pursuant to the sales agreement, a commission in an amount equal to 3.0% of the aggregate gross proceeds from each sale of
our common stock. Because there is no minimum offering amount required as a condition to this offering, the actual total public offering amount, commissions and proceeds to us, if any, are not
determinable at this time. We have agreed to reimburse a portion of Cantor's expenses, including legal fees, in connection with this offering up to a maximum of $50,000. We estimate that the total
expenses for the offering, excluding compensation and expense reimbursement payable to Cantor under the terms of the sales agreement, will be approximately $110,000. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Settlement
for sales of common stock will occur on the second business day following the date on which any sales are made, or on some other date that is agreed upon by us and Cantor in
connection with a particular transaction, in return for payment of the net proceeds to us. There is no arrangement for funds to be received in an escrow, trust or similar arrangement. Sales of our
common stock as contemplated in this prospectus supplement will be settled through the facilities of The Depository Trust Company or by such other means as we and Cantor may agree upon. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cantor
will act as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal laws, rules and
regulations and the rules of Nasdaq. In connection with the sale of the common stock on our behalf, Cantor will be deemed to be an "underwriter" within the meaning of the Securities Act and the
compensation of Cantor will be deemed to be underwriting commissions or discounts. We have agreed to provide indemnification and contribution to Cantor against certain civil liabilities, including
liabilities under the Securities Act. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
offering of our common stock pursuant to the sales agreement will terminate upon the termination of the sales agreement as permitted therein. We or Cantor may each terminate the
sales agreement at any time upon ten (10)&nbsp;days' prior notice. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cantor
and its affiliates may in the future provide various investment banking, commercial banking and other financial services for us and our affiliates, for which services they may in
the future receive customary fees. To the extent required by Regulation&nbsp;M, Cantor will not engage in any market making activities involving our common stock while the offering is ongoing under
this prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus supplement in electronic format may be made available on a website maintained by Cantor, and Cantor may distribute this prospectus supplement electronically. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=13,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1009847,FOLIO='S-11',FILE='DISK133:[20ZCT3.20ZCT40303]DK40303A.;7',USER='JTAYLORA',CD='12-JUN-2020;13:33' -->
<A NAME="page_dk40303_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40303a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dk40303_legal_matters"> </A>
<A NAME="toc_dk40303_2"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lowenstein Sandler&nbsp;LLP, New York, New York, will provide us with an opinion as to the validity of the shares of common stock offered by
this prospectus supplement and the accompanying prospectus. Cantor Fitzgerald&nbsp;&amp;&nbsp;Co. is being represented in connection with this offering by Cooley&nbsp;LLP, New York, New York. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dk40303_experts"> </A>
<A NAME="toc_dk40303_3"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The financial statements incorporated in this Prospectus by reference to the Annual Report on Form 10-K for the year ended December&nbsp;31,
2019 have been so incorporated in reliance on the report (which contains an explanatory paragraph relating to the Company's ability to continue as a going concern as described in Note 1 to the
financial statements) of PricewaterhouseCoopers&nbsp;LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dk40303_where_you_can_find_more_information"> </A>
<A NAME="toc_dk40303_4"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND MORE INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have filed with the SEC a registration statement on Form&nbsp;S-3, including exhibits, under the Securities Act of which this prospectus
supplement and the accompanying prospectus forms&nbsp;a part. This prospectus does not contain all of the information set forth in the registration statement. This prospectus supplement and the
accompanying prospectus are a part of the registration statement but do not contain descriptions of certain agreements or documents that are exhibits to the registration statement. The statements as
to the contents of such exhibits, however, are brief descriptions and are not necessarily complete, and each statement is qualified in all respects by reference to such agreement or document. For
further information about us, please refer to the registration statement and the documents incorporated by reference in this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC's website at </FONT> <FONT SIZE=2><I>http://www.sec.gov</I></FONT><FONT SIZE=2>.
The SEC's website contains reports, proxy statements and other information regarding issuers, such as Celldex
Therapeutics,&nbsp;Inc., that file electronically with the SEC. We make available free of charge through our web site our Annual Report on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q,
Current Reports on Form&nbsp;8-K, Proxy Statements on Schedule&nbsp;14A and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or
furnished to the SEC. Our website address is </FONT><FONT SIZE=2><I>http://www.celldextherapeutics.com</I></FONT><FONT SIZE=2>. Please note that our website address is provided as an inactive textual
reference only. Information contained on or accessible through our website is not part of this prospectus or the prospectus supplement, and is therefore not incorporated by reference unless such
information is otherwise specifically referenced elsewhere in this prospectus or the prospectus supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dk40303_incorporation_of_documents_by_reference"> </A>
<A NAME="toc_dk40303_5"> </A>
<BR></FONT><FONT SIZE=2><B>  INCORPORATION OF DOCUMENTS BY REFERENCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to "incorporate by reference" into this prospectus the information we have filed with the SEC, which means that we can
disclose important information to you by referring you to those documents. Any information that we file subsequently with the SEC will automatically update this prospectus. We incorporate by reference
into this prospectus the information contained in the documents listed below, which is considered to be a part of this prospectus:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/744218/000104746920001809/a2241053z10-k.htm">Our Annual Report on Form&nbsp;10-K
for the fiscal year ended December&nbsp;31, 2019, filed with the SEC on March&nbsp;26, 2020;</A></FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465920057436/tm2014426-1_10q.htm">Our Quarterly Report on
Form&nbsp;10-Q for the fiscal quarter ended March&nbsp;31, 2020, filed on May&nbsp;6, 2020;</A> </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=14,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=52838,FOLIO='S-12',FILE='DISK133:[20ZCT3.20ZCT40303]DK40303A.;7',USER='JTAYLORA',CD='12-JUN-2020;13:33' -->
<A NAME="page_dk40303_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40303a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/744218/000104746920002644/a2241464zdef14a.htm">Our Definitive Proxy Statement on
Schedule&nbsp;14A, filed with the SEC on April&nbsp;28, 2020 (other than the portions thereof which are furnished and not filed); and</A></FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The description of our common stock contained in our Registration Statement on Form&nbsp;8-A, filed on
<A HREF="http://www.sec.gov/Archives/edgar/data/744218/000104746904033435/a2146123z8-a12g.htm">November&nbsp;8, 2004</A>, as amended by Form&nbsp;8-A/A filed on
<A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465907076169/a07-27173_78a12ga.htm">October&nbsp;22, 2007</A> and
<A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465907076169/a07-27173_78a12ga.htm">March&nbsp;7, 2008</A>. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also incorporate by reference all documents we file under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act (a)&nbsp;after the initial filing date of the registration
statement of which this prospectus is a part and before the effectiveness of the registration statement and (b)&nbsp;after the effectiveness of the registration statement and before the filing of a
post-effective amendment that indicates that the securities offered by this prospectus have been sold or that deregisters the securities covered by this prospectus then remaining unsold. The most
recent information that we file with the SEC automatically updates and supersedes older information. The information contained in any such filing will be deemed to be a part of this prospectus,
commencing on the date on which the document is filed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nothing
in this prospectus shall be deemed to incorporate information furnished but not filed with the SEC pursuant to Item&nbsp;2.02 or 7.01 of Form&nbsp;8-K. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will furnish without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any documents incorporated by
reference other than exhibits to those documents. Requests should be addressed to: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Corporate
Secretary<BR>
Celldex Therapeutics,&nbsp;Inc.<BR>
Perryville III Building, 53 Frontage Road, Suite&nbsp;220,<BR>
Hampton, New Jersey 08827<BR>
(908)&nbsp;200-7500 </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
statement contained in this prospectus supplement or in a document incorporated or deemed to be incorporated by reference into this prospectus supplement will be deemed to be
modified or superseded for purposes of this prospectus supplement to the extent that a statement contained in this prospectus supplement or any other subsequently filed document that is deemed to be
incorporated by reference into this prospectus supplement modifies or supersedes the statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to
constitute a part of this prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should rely only on information contained in, or incorporated by reference into, this prospectus supplement and the accompanying prospectus. We have not authorized anyone to provide
you with information different from that contained in this prospectus supplement and the accompanying prospectus or incorporated by reference in this prospectus supplement and the accompanying
prospectus. We are not making offers to sell the securities in any jurisdiction in which such an offer or solicitation is not authorized or in which the person making such offer or solicitation is not
qualified to do so or to anyone to whom it is unlawful to make such offer or solicitation. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>S-13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=15,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=806497,FOLIO='S-13',FILE='DISK133:[20ZCT3.20ZCT40303]DK40303A.;7',USER='JTAYLORA',CD='12-JUN-2020;13:33' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg40304a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B>PROSPECTUS  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g985367.jpg" ALT="GRAPHIC" WIDTH="171" HEIGHT="42">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=2><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>CELLDEX THERAPEUTICS,&nbsp;INC.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=4><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>$150,000,000  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B> Common Stock<BR>
Preferred Stock<BR>
Warrants<BR>
Depositary Shares<BR>
Units  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=4><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Celldex Therapeutics,&nbsp;Inc. may offer, issue and sell from time to time, together or separately, in one or more offerings, any combination
of:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our common stock, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> our preferred stock, which we may issue in one or more series, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> warrants, </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> depositary shares, and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> units, </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>up
to a maximum aggregate offering price of $150,000,000. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus provides a general description of the securities we may offer. Each time we sell securities, we will provide specific terms of the securities offered in a supplement to
this prospectus (which includes an at-the-market offering prospectus). The prospectus supplement may also add, update or change information contained in this prospectus. You should read this
prospectus and the accompanying prospectus supplement, as well as the documents incorporated or deemed incorporated by reference in this prospectus, carefully before you make your investment decision.
Our common stock is traded on the Nasdaq Capital Market under the symbol "CLDX." On June&nbsp;10, 2020, the last reported sale price of our common stock on the Nasdaq Capital Market was $4.80 per
share. You are urged to obtain current market quotations of the common stock. Each prospectus supplement will indicate if the securities offered thereby will be listed on any securities exchange. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus may not be used to sell securities unless accompanied by a prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may offer to sell these securities on a continuous or delayed basis, through agents, dealers or underwriters, or directly to purchasers. The prospectus supplement for each offering of
securities will describe in detail the plan of distribution for that offering. If our agents or any dealers or underwriters are involved in the sale of the securities, the applicable prospectus
supplement will set forth the names of the agents, dealers or underwriters and any applicable commissions or discounts. Our net proceeds from the sale of securities will also be set forth in the
applicable prospectus supplement. For general
information about the distribution of securities offered, please see "Plan of Distribution" in this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=3><B>Investing in our securities involves risks. Before making an investment decisions, you should carefully review the information contained in this
prospectus under the heading "Risk Factors" beginning on page&nbsp;3 of this prospectus.  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><B>NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION OR REGULATORY BODY HAS APPROVED OR
DISAPPROVED OF THESE SECURITIES OR DETERMINED IF THIS PROSPECTUS IS TRUTHFUL OR COMPLETE. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.</B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>The date of this prospectus is June&nbsp;12, 2020.  </B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=16,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=296104,FOLIO='blank',FILE='DISK135:[20ZCT4.20ZCT40304]BC40304A.;10',USER='JTAYLORA',CD='12-JUN-2020;12:45' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_bg40304_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40304a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2><A NAME="BG40304A_main_toc"></A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bg40304_table_of_contents"> </A>
<BR></FONT><FONT SIZE=2><B>  TABLE OF CONTENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>
<A NAME="BG40304_TOC"></A> </FONT></P>
 <div style="display:none;*display:block;margin-top:-1pt;"></div>

 <DIV style="padding:0pt;position:relative;width:80%;margin-left:10%;">
 <!-- COMMAND=ADD_TABLEWIDTH,"100%" -->
<!-- COMMAND=ADD_START_LINKTABLE -->

<!-- User-specified TAGGED TABLE -->
<DIV ALIGN="CENTER"><TABLE width="100%"  BORDER=0 CELLSPACING=0 CELLPADDING=0>
<TR><!-- TABLE COLUMN WIDTHS SET -->
<TD WIDTH="" style="font-family:times;"></TD>
<TD WIDTH="12pt" style="font-family:times;"></TD>
<TD WIDTH="25pt" style="font-family:times;"></TD>
<!-- TABLE COLUMN WIDTHS END --></TR>

<TR VALIGN="BOTTOM">
<TH ALIGN="LEFT" style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT><BR></TH>
<TH style="font-family:times;"><FONT SIZE=1>&nbsp;</FONT></TH>
<TH ALIGN="CENTER" style="font-family:times;border-bottom:solid #000000 1.0pt;"><FONT SIZE=1><B>Page </B></FONT></TH>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#bi40304_about_this_prospectus"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>ABOUT THIS PROSPECTUS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#bi40304_about_this_prospectus"><FONT SIZE=2>1</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#ca40304_prospectus_summary"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PROSPECTUS SUMMARY</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#ca40304_prospectus_summary"><FONT SIZE=2>2</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da40304_special_note_regarding_forward-looking_statements"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da40304_special_note_regarding_forward-looking_statements"><FONT SIZE=2>3</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da40304_risk_factors"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>RISK FACTORS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da40304_risk_factors"><FONT SIZE=2>3</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da40304_use_of_proceeds"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>USE OF PROCEEDS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da40304_use_of_proceeds"><FONT SIZE=2>3</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da40304_descriptions_of_securities_we_may_offer"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTIONS OF SECURITIES WE MAY OFFER</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da40304_descriptions_of_securities_we_may_offer"><FONT SIZE=2>4</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da40304_description_of_common_stock"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF COMMON STOCK</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da40304_description_of_common_stock"><FONT SIZE=2>4</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da40304_description_of_preferred_stock"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF PREFERRED STOCK</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da40304_description_of_preferred_stock"><FONT SIZE=2>5</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#da40304_description_of_warrants"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF WARRANTS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#da40304_description_of_warrants"><FONT SIZE=2>8</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc40304_description_of_depositary_shares"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF DEPOSITARY SHARES</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc40304_description_of_depositary_shares"><FONT SIZE=2>10</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc40304_description_of_units"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>DESCRIPTION OF UNITS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc40304_description_of_units"><FONT SIZE=2>10</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc40304_plan_of_distribution"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>PLAN OF DISTRIBUTION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc40304_plan_of_distribution"><FONT SIZE=2>11</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc40304_legal_matters"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>LEGAL MATTERS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc40304_legal_matters"><FONT SIZE=2>13</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc40304_experts"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>EXPERTS</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc40304_experts"><FONT SIZE=2>13</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc40304_where_you_can_find_more_information"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>WHERE YOU CAN FIND MORE INFORMATION</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc40304_where_you_can_find_more_information"><FONT SIZE=2>13</FONT></A></TD>
</TR>
<TR VALIGN="TOP">
<TD style="font-family:times;"><A HREF="#dc40304_incorporation_of_certain_documents_by_reference"><p style="font-family:times;margin-left:10pt;text-indent:-10pt;"><FONT SIZE=2> </FONT><FONT SIZE=2>INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</FONT></A></TD>
<TD style="font-family:times;"><FONT SIZE=2>&nbsp;</FONT></TD>
<TD ALIGN="RIGHT" VALIGN="BOTTOM" style="font-family:times;"><A HREF="#dc40304_incorporation_of_certain_documents_by_reference"><FONT SIZE=2>13</FONT></A></TD>
</TR>
</TABLE></DIV>
<!-- end of user-specified TAGGED TABLE -->
<!-- COMMAND=ADD_END_LINKTABLE -->
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>i</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=17,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=126226,FOLIO='i',FILE='DISK135:[20ZCT4.20ZCT40304]BG40304A.;3',USER='CHE105939',CD='12-JUN-2020;10:45' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_bi40304_1_1"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40304a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="bi40304_about_this_prospectus"> </A>
<A NAME="toc_bi40304_1"> </A>
<BR></FONT><FONT SIZE=2><B>  ABOUT THIS PROSPECTUS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus is a part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, utilizing a "shelf"
registration process. Under this shelf registration process, we may, from time to time, sell any combination of the securities described in this prospectus in one or more offerings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
registration statement containing this prospectus, including the exhibits to the registration statement, provides additional information about us and the securities offered under
this prospectus. You should read the registration statement and the accompanying exhibits for further information. The registration statement, including the exhibits and the documents incorporated or
deemed incorporated herein by reference, can be read and are available to the public over the Internet at the SEC's website at </FONT><FONT SIZE=2><I>http://www.sec.gov</I></FONT><FONT SIZE=2> as
described under the heading "Where You Can Find More Information." </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
prospectus provides you with a general description of the securities we may offer. Each time we sell securities pursuant to this prospectus, we will provide a prospectus supplement
(which term includes, as applicable, the at-the-market offering prospectus filed with the registration statement of which this prospectus forms&nbsp;a part) containing specific information about the
terms of a particular offering by us. That prospectus supplement may include a discussion of any risk factors or other special considerations that apply to those securities. The prospectus supplement
may add, update or change information in this prospectus. If the information in the prospectus is inconsistent with a prospectus supplement, you should rely on the information in that prospectus
supplement. You should read both this prospectus and, if applicable, any prospectus supplement. See "Where You Can Find More Information" for more information. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
should rely only on the information incorporated by reference or provided in this prospectus or any prospectus supplement. We have not authorized any dealer, salesman or other person
to give any information or to make any representation other than those contained or incorporated by reference in this prospectus or any prospectus supplement. You must not rely upon any information or
representation not contained or incorporated by reference in this prospectus or any prospectus supplement. This prospectus and any prospectus supplement do not constitute an offer to sell or the
solicitation of an offer to buy any securities other than the registered securities to which they relate, nor do this prospectus and any prospectus supplement constitute an offer to sell or the
solicitation of an offer to buy securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. You should not assume that the information
contained in this prospectus or any prospectus supplement is accurate on any date subsequent to the date set forth on the front of such document or that any information we have incorporated by
reference is correct on any date subsequent to the date of the document incorporated by reference, even though this prospectus and any prospectus supplement is delivered or securities are sold on a
later date. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT
SIZE=2><I>Unless this prospectus indicates otherwise or the context otherwise requires, the terms "we," "our," "us," "Celldex" or the "Company" as used in this prospectus
refer to Celldex Therapeutics,&nbsp;Inc. and its subsidiaries, except that such terms refer to only Celldex Therapeutics,&nbsp;Inc. and not its subsidiaries in the sections entitled "Description
of Common Stock," "Description of Preferred Stock," "Description of Warrants," "Description of Depositary Shares," and "Description of Units."</I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>1</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=18,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1046210,FOLIO='1',FILE='DISK135:[20ZCT4.20ZCT40304]BI40304A.;2',USER='CHE105939',CD='12-JUN-2020;10:15' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_ca40304_1_2"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40304a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><I> </i></font></p>
<DIV style="width:100%;box-sizing:border-box;border:#000000 solid 1.0pt;padding-top:12.0pt;padding-right:12.0pt;padding-bottom:12.0pt;padding-left:12.0pt;">
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="ca40304_prospectus_summary"> </A>
<A NAME="toc_ca40304_1"> </A>
<BR></FONT><FONT SIZE=2><B>  PROSPECTUS SUMMARY    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a biopharmaceutical company focused on the development and commercialization of immunotherapies and other targeted biologics. Our drug
candidates are derived from a broad set of human and bispecific antibodies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or
other diseases. They are aimed at addressing market opportunities for which we believe current therapies are inadequate or non-existent. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
are focusing our efforts and resources on the continued research and development of:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> CDX-0159, a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which recently completed a
Phase&nbsp;1a study in healthy volunteers where it demonstrated a favorable safety profile as well as profound and durable reductions of plasma tryptase, consistent with systemic mast cell
suppression. We plan to study CDX-0159 in mast cell driven diseases, including, initially, chronic spontaneous urticaria (CSU) and chronic inducible urticarias (CINDUs); </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> CDX-1140, an agonist monoclonal antibody targeted to CD40, a key activator of immune response, currently being studied as a single-agent and in
combination with CDX-301, a dendritic cell growth factor. Dose escalation was recently completed in a Phase&nbsp;1 study in solid tumors and lymphoma and the recommended dose for further study was
determined to be 1.5&nbsp;mg/kg, one of the highest systemic dose levels in the CD40 agonist class, for both CDX-1140 monotherapy and in combination with CDX-301. Celldex has initiated multiple
expansion cohorts within the study, including a combination cohort with KEYTRUDA&reg; (pembrolizumab). The Company is exploring additional combination cohorts with mechanisms that we believe
could be complementary or synergistic with CDX-1140; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> CDX-3379, a monoclonal antibody designed to block the activity of ErbB3 (HER3), currently in an early Phase&nbsp;2 study in advanced head and
neck squamous cell cancer in combination with Erbitux&reg;<SUP>;</SUP> and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> CDX-527, a bispecific antibody that uses our proprietary highly active anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with
blockade of the PD-L1/PD-1 pathway, for which we are planning a Phase&nbsp;1 study in advanced solid tumors. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
routinely work with external parties to collaboratively advance our drug candidates. In addition to Celldex-led studies, we also have an Investigator Initiated Research (IIR) program
with multiple studies ongoing with our drug candidates. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
goal is to build a fully integrated, commercial-stage biopharmaceutical company that develops important therapies for patients with unmet medical needs. We believe our program assets
provide us with the strategic options to either retain full economic rights to our innovative therapies or seek favorable economic terms through advantageous commercial partnerships. This approach
allows us to maximize the overall value of our technology and product portfolio while best ensuring the expeditious development of each individual product. Currently, all programs are fully owned by
Celldex. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Corporate Information  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We are a Delaware corporation organized in 1983. Our principal executive offices are located at Perryville III Building, 53 Frontage Road,
Suite&nbsp;220, Hampton, New Jersey 08827 and our telephone number is (908)&nbsp;200-7500. Our corporate website is www.celldex.com. The information on our website is not incorporated by reference
into this prospectus. </FONT></P>
 </DIV>
 <P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>2</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=19,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=977750,FOLIO='2',FILE='DISK135:[20ZCT4.20ZCT40304]CA40304A.;4',USER='CHE105939',CD='12-JUN-2020;10:59' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_da40304_1_3"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40304a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da40304_special_note_regarding_forward-looking_statements"> </A>
<A NAME="toc_da40304_1"> </A>
<BR></FONT><FONT SIZE=2><B>  SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus, including the documents that we incorporate by reference, contains forward-looking statements within the meaning of
Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Any statements
about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but not always, made
through the use of words or phrases such as "anticipate," "estimate," "plans," "projects," "continuing," "ongoing," "expects," "management believes," "we believe," "we intend" and similar words or
phrases. Accordingly, these statements involve estimates, assumptions and uncertainties, which could cause actual results to differ materially from those expressed in them. Any forward-looking
statements are qualified in their entirety by reference to the risk factors discussed in this prospectus or discussed in documents incorporated by reference in this prospectus. </FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Forward-looking
statements are subject to known and unknown risks and uncertainties, which change over time, and are based on management's expectations and assumptions at the time the
statements are made, and are not guarantees of future results. Our actual results may differ materially from those expressed or anticipated in the forward-looking statements for many reasons including
the factors described in the section entitled "Risk Factors" in this prospectus and in any risk factors described in a supplement to this prospectus or in other filings. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;You
are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. We undertake no obligation to publicly revise
any forward-looking statement to reflect circumstances or events after the date of this prospectus or to reflect the occurrence of unanticipated events. You should, however, review the factors and
risks we describe in the reports we file from time to time with the SEC after the date of this prospectus. We undertake no obligation to revise or update the forward-looking statements contained in
this prospectus at any time. All forward-looking statements are qualified in their entirety by this cautionary statement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da40304_risk_factors"> </A>
<A NAME="toc_da40304_2"> </A>
<BR></FONT><FONT SIZE=2><B>  RISK FACTORS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><FONT SIZE=2><I>Investing in our securities involves significant risks. Before making an investment decision, you should carefully
consider the risks and other information we include or incorporate by reference in this prospectus and any prospectus supplement. In particular, you should consider the risk factors under the heading
"Risk Factors" included in our most recent Annual Report on Form&nbsp;10-K, as may be revised or supplemented by our subsequent Quarterly Reports on Form&nbsp;10-Q or Current Reports on
Form&nbsp;8-K, each of which are on file with the SEC and are incorporated herein by reference, and which may be amended, supplemented or superseded from time to time by other reports we file with
the SEC in the future. The risks and uncertainties we have described are not the only ones facing our company. Additional risks and uncertainties not currently known to us or that we currently deem
immaterial may also affect our business operations. Additional risk factors may be included in a prospectus supplement relating to a particular offering of securities. Our business, financial
condition or results of operations could be materially adversely affected by any of these risks. The trading price of our securities could decline due to any of these risks, and you may lose all or
part of your investment. This prospectus is qualified in its entirety by these risk factors.</I></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da40304_use_of_proceeds"> </A>
<A NAME="toc_da40304_3"> </A>
<BR></FONT><FONT SIZE=2><B>  USE OF PROCEEDS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise provided in the applicable prospectus supplement to this prospectus used to offer specific securities, we expect to use the net
proceeds from any offering of securities by us for general corporate purposes, which may include acquisitions, capital expenditures, investments, payment of milestone payments, and the repayment,
redemption or refinancing of all or a portion of any indebtedness or other securities outstanding at a particular time, to fund our operations
until we receive FDA approval of our products and are able to commercialize our products and to make </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>3</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=20,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=781105,FOLIO='3',FILE='DISK135:[20ZCT4.20ZCT40304]DA40304A.;4',USER='CHE105939',CD='12-JUN-2020;10:52' -->
<A NAME="page_da40304_1_4"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40304a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>substantial
investments to establish sales, marketing, quality control, and regulatory compliance capabilities in anticipation of FDA approval of our products. Pending the application of the net
proceeds, we expect to invest the net proceeds in short-term, interest-bearing instruments with a maturity of three months or less at the date of purchase and consist primarily of investments in money
market mutual funds with commercial banks and financial institutions or other investment-grade securities. Such investments may include depositing such net proceeds into, and maintaining cash balances
with, financial institutions in excess of insured limits. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da40304_descriptions_of_securities_we_may_offer"> </A>
<A NAME="toc_da40304_4"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTIONS OF SECURITIES WE MAY OFFER    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This prospectus contains summary descriptions of the common stock, preferred stock, warrants, depositary shares and units that we may offer and
sell from time to time. The preferred stock may also be exchangeable for and/or convertible into shares of common stock or another series of preferred stock. When one or more of these securities are
offered in the future, a prospectus supplement will explain the particular terms of the securities and the extent to which these general provisions may apply. These summary descriptions and any
summary descriptions in the applicable prospectus supplement do not purport to be complete descriptions of the terms and conditions of each security and are qualified in their entirety by reference to
our third restated certificate of incorporation, as amended, our by-laws and by applicable Delaware law and any other documents referenced in such summary descriptions and from which such summary
descriptions are derived. If any particular terms of a security described in the applicable prospectus supplement differ from any of the terms described herein, then the terms described herein will be
deemed superseded by the terms set forth in that prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may issue securities in book-entry form through one or more depositaries, such as The Depository Trust Company, Euroclear or Clearstream, named in the applicable prospectus
supplement. Each sale of a security in book-entry form will settle in immediately available funds through the applicable depositary, unless otherwise stated. We will issue the securities only in
registered form, without coupons, although we may issue the securities in bearer form if so specified in the applicable prospectus supplement. If any securities are to be listed or quoted on a
securities exchange or quotation system, the applicable prospectus supplement will say so. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da40304_description_of_common_stock"> </A>
<A NAME="toc_da40304_5"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF COMMON STOCK    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;As of June&nbsp;10, 2020 we are authorized to issue up to 297,000,000 shares of common stock, $0.001 par value per share. As of
June&nbsp;10, 2020, approximately 20,675,269 shares of common stock were outstanding. All outstanding shares of our common stock are fully paid and non-assessable. Our common stock is listed on the
Nasdaq Capital Market under the symbol "CLDX". </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Dividends  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Board of Directors may, out of funds legally available, at any regular or special meeting, declare dividends to the holders of shares of our
common stock as and when they deem expedient, subject to the rights of holders of the preferred stock, if any. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Voting  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each share of common stock entitles the holders to one vote per share on all matters requiring a vote of the stockholders, including the
election of directors. No holders of shares of common stock shall have the right to vote such shares cumulatively in any election for the board of directors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>4</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=21,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=508078,FOLIO='4',FILE='DISK135:[20ZCT4.20ZCT40304]DA40304A.;4',USER='CHE105939',CD='12-JUN-2020;10:52' -->
<A NAME="page_da40304_1_5"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40304a_main_toc">Table of Contents</A></FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Rights Upon Liquidation  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;In the event of our voluntary or involuntary liquidation, dissolution, or winding up, the holders of our common stock will be entitled to share
equally in our assets available for distribution after payment in full of all debts and after the holders of preferred stock, if any, have received their liquidation preferences in full. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Miscellaneous  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No holders of shares of our common stock shall have any preemptive rights to subscribe for, purchase or receive any shares of any class, whether
now or hereafter authorized, or any options or warrants to purchase any such shares, or any securities convertible into or exchanged for any such shares, which may at any time be issued, sold or
offered for sale by Celldex. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Anti-Takeover Provisions  </I></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Certain provisions in our third restated certificate of incorporation, as amended, and applicable Delaware corporate, as well as our shareholder
rights agreement, may have the effect of discouraging a change of control of Celldex, even if such a transaction is favored by some of our stockholders and could result in stockholders receiving a
substantial premium over the current market price of our shares. The primary purpose of these provisions is to encourage negotiations with our management by persons interested in acquiring control of
our corporation. These provisions may also tend to perpetuate present management and make it difficult for stockholders owning less than a majority of the shares to be able to elect even a single
director. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Computershare
Trust Company, N.A. is presently the transfer agent and registrar for our common stock. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da40304_description_of_preferred_stock"> </A>
<A NAME="toc_da40304_6"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF PREFERRED STOCK    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;At June&nbsp;10, 2020, the Company had authorized preferred stock comprised of 3,000,000 shares of Class&nbsp;C Preferred Stock of which
350,000 shares has been designated as Class&nbsp;C-1&nbsp;Junior Participating Cumulative Preferred Stock, the terms of which are to be determined by our Board of Directors. As of June&nbsp;10,
2020, there was no preferred stock outstanding. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Class&nbsp;C Preferred Stock  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This section describes the general terms and provisions of our Class&nbsp;C Preferred Stock. The applicable prospectus supplement will
describe the specific terms of the shares of preferred stock offered through that prospectus supplement, as well as any general terms described in this section that will not apply to those shares of
preferred stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors has been authorized to provide for the issuance of the 2,650,000 unissued and undesignated shares of our Class&nbsp;C Preferred Stock In general, our third
restated certificate of incorporation, as amended, authorizes our board of directors to issue new shares of our common stock or preferred stock without further stockholder action, provided that there
are sufficient authorized shares. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;With
respect to each series of our Class&nbsp;C Preferred Stock, our board of directors has the authority to fix the following terms:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the designation of the series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of shares within the series; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>5</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=22,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=455593,FOLIO='5',FILE='DISK135:[20ZCT4.20ZCT40304]DA40304A.;4',USER='CHE105939',CD='12-JUN-2020;10:52' -->
<A NAME="page_da40304_1_6"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40304a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether dividends are cumulative and, if cumulative, the dates from which dividends are cumulative; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the rate of any dividends, any conditions upon which dividends are payable, and the dates of payment of dividends; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether interests in the shares of preferred stock will be represented by depositary shares as more fully described below under "Description of
Depositary Shares"; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the shares are redeemable, the redemption price and the terms of redemption; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the amount payable to you for each share you own if we dissolve or liquidate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the shares are convertible or exchangeable, the price or rate of conversion or exchange, and the applicable terms and conditions; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any restrictions on issuance of shares in the same series or any other series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> voting rights applicable to the series of preferred stock; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other rights, priorities, preferences, restrictions or limitations of such series. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
rights with respect to any shares of our Class&nbsp;C Preferred Stock will be subordinate to the rights of our general creditors. Shares of our Class&nbsp;C Preferred Stock that
we issue in accordance with their terms will be fully paid and nonassessable, and will not be entitled to preemptive rights unless specified in the applicable prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
ability to issue preferred stock, or rights to purchase such shares, could discourage an unsolicited acquisition proposal. For example, we could impede a business combination by
issuing a series of preferred stock containing class voting rights that would enable the holders of such preferred stock to block a business combination transaction. Alternatively, we could facilitate
a business combination transaction by issuing a series of preferred stock having sufficient voting rights to provide a required percentage vote of the stockholders. Additionally, under certain
circumstances, our issuance of preferred stock could adversely affect the voting power of the holders of our common stock. Although our board of directors is required to make any determination to
issue any preferred stock based on its judgment as to the best interests of our stockholders, our board of directors could act in a manner that would discourage an acquisition attempt or other
transaction that some, or a majority, of our stockholders might believe to be in their best interests or in which stockholders might receive a premium for their stock over prevailing market prices of
such stock. Our board of directors does not at present intend to seek stockholder approval prior to any issuance of currently authorized stock, unless otherwise required by law or applicable stock
exchange requirements. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B><I>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Terms of the Preferred Stock That We May Offer and Sell to You  </I></B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We summarize below some of the provisions that will apply to the preferred stock that we may offer to you unless the applicable prospectus
supplement provides otherwise. This summary may not contain all information that is important to you. You should read the prospectus
supplement, which will contain additional information and which may update or change some of the information below. Prior to the issuance of a new series of preferred stock, we will further amend our
third restated certificate of incorporation, as amended, designating the stock of that series and the terms of that series. We will file&nbsp;a copy of the certificate of designation that contains
the terms of each new series of preferred stock with the SEC each time we issue a new series of preferred stock. Each certificate of designation will establish the number of shares included in a
designated series and fix the designation, powers, privileges, preferences and rights of the shares of each series as well as any applicable qualifications, limitations or restrictions. You should
refer to the applicable certificate of designation as well as our </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>6</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=23,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=811295,FOLIO='6',FILE='DISK135:[20ZCT4.20ZCT40304]DA40304A.;4',USER='CHE105939',CD='12-JUN-2020;10:52' -->
<A NAME="page_da40304_1_7"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40304a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>third
restated certificate of incorporation, as amended, before deciding to buy shares of our preferred stock as described in the applicable prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors has the authority, without further action by the stockholders, to issue preferred stock in one or more series and to fix the number of shares, dividend rights,
conversion rights, voting rights, redemption rights, liquidation preferences, sinking funds, and any other rights, preferences, privileges and restrictions applicable to each such series of preferred
stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
issuance of any preferred stock could adversely affect the rights of the holders of common stock and, therefore, reduce the value of the common stock. The ability of our board of
directors to issue preferred stock could discourage, delay or prevent a takeover or other corporate action. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
terms of any particular series of preferred stock will be described in the prospectus supplement relating to that particular series of preferred stock, including, where
applicable:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the designation, stated value and liquidation preference of such preferred stock; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the number of shares within the series; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the offering price; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the dividend rate or rates (or method of calculation), the date or dates from which dividends shall accrue, and whether such dividends shall be
cumulative or noncumulative and, if cumulative, the dates from which dividends shall commence to cumulate; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether interests in the shares of preferred stock will be represented by depositary shares as more fully described below under "Description of
Depositary Shares"); </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any redemption or sinking fund provisions; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the amount that shares of such series shall be entitled to receive in the event of our liquidation, dissolution or winding-up; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the terms and conditions, if any, on which shares of such series shall be convertible or exchangeable for shares of our stock of any other
class or classes, or other series of the same class; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the voting rights, if any, of shares of such series; the status as to reissuance or sale of shares of such series redeemed, purchased or
otherwise reacquired, or surrendered to us on conversion or exchange; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the conditions and restrictions, if any, on the payment of dividends or on the making of other distributions on, or the purchase, redemption or
other acquisition by us or any subsidiary, of the common stock or of any other class of our shares ranking junior to the shares of such series as to dividends or upon liquidation; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the conditions and restrictions, if any, on the creation of indebtedness by us or by any subsidiary, or on the issuance of any additional stock
ranking on a parity with or prior to the shares of such series as to dividends or upon liquidation; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any additional dividend, liquidation, redemption, sinking or retirement fund and other rights, preferences, privileges, limitations and
restrictions of such preferred stock. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
description of the terms of a particular series of preferred stock in the applicable prospectus supplement will not be complete. You should refer to the applicable amendment to our
third restated certificate of incorporation, as amended, for complete information regarding a series of preferred stock. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
preferred stock will, when issued against payment of the consideration payable therefor, be fully paid and nonassessable. Unless otherwise specified in the applicable prospectus
supplement, each </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>7</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=24,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=899947,FOLIO='7',FILE='DISK135:[20ZCT4.20ZCT40304]DA40304A.;4',USER='CHE105939',CD='12-JUN-2020;10:52' -->
<A NAME="page_da40304_1_8"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40304a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>series
of preferred stock will, upon issuance, rank senior to the common stock and on a parity in all respects with each other outstanding series of preferred stock. The rights of the holders of our
preferred stock will be subordinate to that of our general creditors. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="da40304_description_of_warrants"> </A>
<A NAME="toc_da40304_7"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF WARRANTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We summarize below some of the provisions that will apply to the warrants unless the applicable prospectus supplement provides otherwise. This
summary may not contain all information that is important to you. The complete terms of the warrants will be contained in the applicable warrant certificate and warrant agreement. These documents have
been or will be included or incorporated by reference as exhibits to the registration statement of which this prospectus is a part. You should read the warrant certificate and the warrant agreement.
You should also read the prospectus supplement, which will contain additional information and which may update or change some of the information below. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue, together with other securities or separately, warrants to purchase common stock, preferred stock or other securities. We may issue
the warrants under warrant agreements to be entered into between us and a bank or trust company, as warrant agent, all as set forth in the applicable prospectus supplement. The warrant agent would act
solely as our agent in connection with the warrants of the series being offered and would not assume any obligation or relationship of agency or trust for or with any holders or beneficial owners of
warrants. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
applicable prospectus supplement will describe the following terms, where applicable, of warrants in respect of which this prospectus is being
delivered:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the title of the warrants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the designation, amount and terms of the securities for which the warrants are exercisable and the procedures and conditions relating to the
exercise of such warrants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the designation and terms of the other securities, if any, with which the warrants are to be issued and the number of warrants issued with each
such security; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the price or prices at which the warrants will be issued; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the aggregate number of warrants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any provisions for adjustment of the number or amount of securities receivable upon exercise of the warrants or the exercise price of the
warrants; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the price or prices at which the securities purchasable upon exercise of the warrants may be purchased; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if applicable, the date on and after which the warrants and the securities purchasable upon exercise of the warrants will be separately
transferable; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if applicable, a discussion of the material U.S. federal income tax considerations applicable to the warrants; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other terms of the warrants, including terms, procedures and limitations relating to the exchange and exercise of the warrants; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the date on which the right to exercise the warrants shall commence and the date on which the right shall expire; </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>8</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=6,SEQ=25,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=1030365,FOLIO='8',FILE='DISK135:[20ZCT4.20ZCT40304]DA40304A.;4',USER='CHE105939',CD='12-JUN-2020;10:52' -->
<A NAME="page_da40304_1_9"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40304a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> if applicable, the maximum or minimum number of warrants which may be exercised at any time; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the identity of the warrant agent; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any mandatory or optional redemption provision; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the warrants are to be issued in registered or bearer form; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the warrants are extendible and the period or periods of such extendibility; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> information with respect to book-entry procedures, if any; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any other terms of the warrants. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Before
exercising their warrants, holders of warrants will not have any of the rights of holders of the securities purchasable upon such exercise, including the right to receive
dividends, if any, or payments upon our liquidation, dissolution or winding-up or to exercise voting rights, if any. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>



<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Exercise of Warrants  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each warrant will entitle the holder thereof to purchase such number of shares of common stock or preferred stock or other securities at the
exercise price as will in each case be set forth in, or be determinable as set forth in, the applicable prospectus supplement. Warrants may be exercised at any time up to the close of business on the
expiration date set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. Warrants may be exercised as set forth in
the applicable prospectus supplement relating to the warrants offered thereby. Upon receipt of payment and the warrant certificate properly completed and duly executed at the corporate trust office of
the warrant agent or any other office indicated in the applicable prospectus supplement, we will, as soon as practicable, forward the purchased securities. If less than all of the warrants represented
by the warrant certificate are exercised, a new warrant certificate will be issued for the remaining warrants. </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Enforceability of Rights of Holders of Warrants  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Each warrant agent will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of
agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue of warrants. A warrant agent will have no duty or responsibility in case
of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder
of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable
upon exercise of, that holder's warrant(s). </FONT></P>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


Modification of the Warrant Agreement  </B></FONT></P>


<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The warrant agreement will permit us and the warrant agent, without the consent of the warrant holders, to supplement or amend the agreement in
the following circumstances:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to cure any ambiguity; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to correct or supplement any provision which may be defective or inconsistent with any other provisions; or </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> to add new provisions regarding matters or questions that we and the warrant agent may deem necessary or desirable and which do not adversely
affect the interests of the warrant holders. </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>9</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=7,SEQ=26,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=878018,FOLIO='9',FILE='DISK135:[20ZCT4.20ZCT40304]DA40304A.;4',USER='CHE105939',CD='12-JUN-2020;10:52' -->
<UL>
<UL>
</UL>
</UL>
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2><A NAME="page_dc40304_1_10"> </A>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->





<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->




<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT></P>

<!-- TOC_END -->

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40304a_main_toc">Table of Contents</A> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc40304_description_of_depositary_shares"> </A>
<A NAME="toc_dc40304_1"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF DEPOSITARY SHARES    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We summarize below some of the provisions that will apply to depositary shares unless the applicable prospectus supplement provides otherwise.
This summary may not contain all information that is important to you. The complete terms of the depositary shares will be contained in the depositary agreement and depositary receipt applicable to
any depositary shares. These documents have been or will be included or incorporated by reference as exhibits to the registration statement of which this prospectus is a part. You should read the
depositary agreement and the depositary receipt. You should also read the prospectus supplement, which will contain additional information and which may update or change some of the information below. </FONT></P>

<UL>

<P style="font-family:times;;margin-left:10.0pt;text-indent:-10.0pt;"><FONT SIZE=2><B>


<!-- COMMAND=STYLE_ADDED,"margin-left:10.0pt;text-indent:-10.0pt;" -->


General  </B></FONT></P>

</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may, at our option, elect to offer fractional or multiple shares of common stock or preferred stock, rather than single shares of common
stock or preferred stock (to be set forth in the prospectus supplement relating to such depositary shares). In the event we elect to do so, depositary receipts evidencing depositary shares will be
issued to the public. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
shares of common stock or any class or series of preferred stock represented by depositary shares will be deposited under a deposit agreement among us, a depositary selected by us,
and the holders of the depositary receipts. The depositary will be a bank or trust company having its principal office in the United States and having a combined capital and surplus of at least
$50,000,000. Subject to the terms of the deposit agreement, each owner of a depositary share will be entitled, in proportion to the applicable fraction of a share of common stock or preferred stock
represented by such depositary share, to all the rights and preferences of the shares of common stock or preferred stock represented by the depositary share, including dividend, voting, redemption and
liquidation rights. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
depositary shares will be evidenced by depositary receipts issued pursuant to the deposit agreement. Depositary receipts will be distributed to those persons purchasing the
fractional shares of common stock or the related class or series of preferred shares in accordance with the terms of the offering described in the related prospectus supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc40304_description_of_units"> </A>
<A NAME="toc_dc40304_2"> </A>
<BR></FONT><FONT SIZE=2><B>  DESCRIPTION OF UNITS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may issue units comprised of one or more of the other securities described in this prospectus in any combination. Each unit will be issued so
that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit
agreement under which a unit is issued may provide that the securities included in the unit may not be held or transferred separately, at any time or at any time before a specified date. The
applicable prospectus supplement may describe:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those
securities may be held or transferred separately; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any provisions for the issuance, payment, settlement, transfer or exchange of the units or of the securities comprising the units; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the terms of the unit agreement governing the units; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> United States federal income tax considerations relevant to the units; and </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> whether the units will be issued in fully registered global form. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
summary of certain general terms of units and any summary description of units in the applicable prospectus supplement do not purport to be complete and are qualified in their
entirety by reference to all provisions of the applicable unit agreement and, if applicable, collateral arrangements </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>10</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=27,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=578507,FOLIO='10',FILE='DISK135:[20ZCT4.20ZCT40304]DC40304A.;6',USER='CHE105939',CD='12-JUN-2020;11:02' -->
<A NAME="page_dc40304_1_11"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40304a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>and
depositary arrangements relating to such units. The forms of the unit agreements and other documents relating to a particular issue of units will be filed with the SEC each time we issue units,
and you should read those documents for provisions that may be important to you. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc40304_plan_of_distribution"> </A>
<A NAME="toc_dc40304_3"> </A>
<BR></FONT><FONT SIZE=2><B>  PLAN OF DISTRIBUTION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We may sell the securities covered hereby from time to time pursuant to underwritten public offerings, direct sales to the public, negotiated
transactions, block trades or a combination of these methods. A distribution of the securities offered by this prospectus may also be effected through the issuance of derivative securities, including
without limitation, warrants and subscriptions. We may sell the securities to or through underwriters or dealers, through agents, or directly to one or more purchasers. We may distribute securities
from time to time in one or more transactions:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at a fixed price or prices, which may be changed; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at market prices prevailing at the time of sale; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at prices related to such prevailing market prices; </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at varying prices determined at the time of sale; or </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> at negotiated prices. </FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> A prospectus supplement or supplements will describe the terms of the offering of the securities, including: </FONT> <FONT SIZE=2>
<BR><BR></FONT>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the name or names of the underwriters, dealers or agents participating in the offering, if any;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> the purchase price of the securities sold by us to any underwriter or dealer and the net proceeds we expect to receive from the
offering;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any over-allotment options under which underwriters may purchase additional securities from us;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any agency fees or underwriting discounts or commissions and other items constituting agents' or underwriters' compensation; </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any public offering price;  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any discounts or concessions allowed or reallowed or paid to dealers; and  </FONT> <FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> any securities exchange or market on which the securities may be listed. </FONT></DD></DL>
</DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Only
underwriters named in the prospectus supplement will be underwriters of the securities offered by the prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
underwriters are used in the sale, they will acquire the securities for their own account and may resell the securities from time to time in one or more transactions at a fixed public
offering price or at
varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement. We
may offer the securities to the public through underwriting syndicates represented by managing underwriters or by underwriters without a syndicate. Subject to certain conditions, the underwriters will
be obligated to purchase all of the securities offered by the prospectus supplement, other than securities covered by any over-allotment option. Any public offering price and any discounts or
commissions or concessions allowed or reallowed or paid to dealers may change from time to time. We may use underwriters with whom we have a material relationship. We will describe in the prospectus
supplement, naming the underwriter, the nature of any such relationship. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>11</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=2,SEQ=28,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=830099,FOLIO='11',FILE='DISK135:[20ZCT4.20ZCT40304]DC40304A.;6',USER='CHE105939',CD='12-JUN-2020;11:02' -->
<A NAME="page_dc40304_1_12"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40304a_main_toc">Table of Contents</A></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may sell securities directly or through agents we designate from time to time. We will name any agent involved in the offering and sale of securities and we will describe any
commissions and other compensation we will pay the agent in the prospectus supplement. Unless the prospectus supplement states otherwise, our agent will act on a best-efforts basis for the period of
its appointment. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may authorize agents or underwriters to solicit offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the
prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We will describe the conditions to these contracts and the
commissions we must pay for solicitation of these contracts in the prospectus supplement. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
may provide agents and underwriters with indemnification against civil liabilities related to this offering, including liabilities under the Securities Act, or contribution with
respect to payments that the agents or underwriters may make with respect to these liabilities. Agents and underwriters may engage in transactions with, or perform services for, us in the ordinary
course of business. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All
securities we may offer, other than common stock, will be new issues of securities with no established trading market. Any agents or underwriters may make a market in these
securities, but will not be obligated to do so and may discontinue any market making at any time without notice. We cannot guarantee the liquidity of the trading markets for any securities. There is
currently no market for any of the offered securities, other than our common stock which is listed on the Nasdaq Capital Market. We have no current plans for listing of the preferred stock, warrants
or subscription rights on any securities exchange or quotation system; any such listing with respect to any particular preferred stock, warrants or subscription rights will be described in the
applicable prospectus supplement or other offering materials, as the case may be. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
underwriter may engage in overallotment, stabilizing transactions, short covering transactions and penalty bids in accordance with Regulation&nbsp;M under the Exchange Act.
Overallotment involves sales in excess of the offering size, which create a short position. Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do
not exceed a specified maximum. Short covering transactions involve purchases of the securities in the open market after the distribution is completed to cover short positions. Penalty bids permit the
underwriters to reclaim a selling concession from a dealer when the securities originally sold by the dealer are purchased in a stabilizing or covering transaction to cover short positions. Those
activities may cause the price of the securities to be higher than it would otherwise be. If commenced, the underwriters may discontinue any of the activities at any time. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
agents and underwriters who are qualified market makers on the Nasdaq Capital Market may engage in passive market making transactions in the securities on the Nasdaq Capital Market
in accordance with Regulation&nbsp;M, during the business day prior to the pricing of the offering, before the commencement of offers or sales of the securities. Passive market makers must comply
with applicable volume and price limitations and must be identified as passive market makers. In general, a passive market maker must display its bid at a price not in excess of the highest
independent bid for such security; if all independent bids are lowered below the passive market maker's bid, however, the passive market maker's bid must then be lowered when certain purchase limits
are exceeded. Passive market making may stabilize the market price of the securities at a level above that which might otherwise prevail in the open market and, if commenced, may be discontinued at
any time. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>12</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=3,SEQ=29,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=36758,FOLIO='12',FILE='DISK135:[20ZCT4.20ZCT40304]DC40304A.;6',USER='CHE105939',CD='12-JUN-2020;11:02' -->
<A NAME="page_dc40304_1_13"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40304a_main_toc">Table of Contents</A></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc40304_legal_matters"> </A>
<A NAME="toc_dc40304_4"> </A>
<BR></FONT><FONT SIZE=2><B>  LEGAL MATTERS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unless otherwise indicated in the applicable prospectus supplement, the validity of the securities offered hereby will be passed upon for us by
Lowenstein Sandler&nbsp;LLP, New York, New York. If the validity of the securities offered hereby in connection with offerings made pursuant to this prospectus are passed upon by counsel for the
underwriters, dealers or agents, if any, such counsel will be named in the prospectus supplement relating to such offering. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc40304_experts"> </A>
<A NAME="toc_dc40304_5"> </A>
<BR></FONT><FONT SIZE=2><B>  EXPERTS    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The financial statements incorporated in this Prospectus by reference to the
<A HREF="http://www.sec.gov/Archives/edgar/data/744218/000104746920001809/a2241053z10-k.htm">Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2019</A>
have been so incorporated in reliance on the report (which contains an explanatory paragraph relating to the Company's ability to continue as a going concern as described in Note&nbsp;1 to the
financial statements) of PricewaterhouseCoopers&nbsp;LLP, an independent registered public accounting firm, given on the authority of said firm as experts in auditing and accounting. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc40304_where_you_can_find_more_information"> </A>
<A NAME="toc_dc40304_6"> </A>
<BR></FONT><FONT SIZE=2><B>  WHERE YOU CAN FIND MORE INFORMATION    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We have filed with the SEC a registration statement on Form&nbsp;S-3, including exhibits, under the Securities Act of which this prospectus
forms&nbsp;a part. This prospectus does not contain all of the information set forth in the registration statement. This prospectus contains descriptions of certain agreements or documents that are
exhibits to the registration statement. The statements as to the contents of such exhibits, however, are brief descriptions and are not necessarily complete, and each statement is qualified in all
respects by reference to such agreement or document. For further information about us, please refer to the registration statement and the documents incorporated by reference in this prospectus. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
file annual, quarterly and current reports, proxy statements and other information with the SEC. Our SEC filings are available to the public over the Internet at the SEC's website at </FONT> <FONT SIZE=2><I>http://www.sec.gov</I></FONT><FONT SIZE=2>.
The SEC's website contains reports, proxy statements and other information regarding issuers, such as Celldex
Therapeutics,&nbsp;Inc., that file electronically with the SEC. We make available free of charge through our web site our Annual Report on Form&nbsp;10-K, Quarterly Reports on Form&nbsp;10-Q,
Current Reports on Form&nbsp;8-K, Proxy Statements on Schedule&nbsp;14A and all amendments to those reports as soon as reasonably practicable after such material is electronically filed with or
furnished to the SEC. Our website address is </FONT><FONT SIZE=2><I>http://www.celldextherapeutics.com</I></FONT><FONT SIZE=2>. Please note that our website address is provided as an inactive textual
reference only. Information contained on or accessible through our website is not part of this prospectus or the prospectus supplement, and is therefore not incorporated by reference unless such
information is otherwise specifically referenced elsewhere in this prospectus or the prospectus supplement. </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><A NAME="dc40304_incorporation_of_certain_documents_by_reference"> </A>
<A NAME="toc_dc40304_7"> </A>
<BR></FONT><FONT SIZE=2><B>  INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE    <BR>    </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The SEC allows us to "incorporate by reference" into this prospectus the information we have filed with the SEC, which means that we can
disclose important information to you by referring you to those documents. Any information that we file subsequently with the SEC will automatically update this prospectus. We incorporate by reference
into this prospectus the information contained in the documents listed below, which is considered to be a part of this prospectus:</FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/744218/000104746920001809/a2241053z10-k.htm">Our Annual Report on Form&nbsp;10-K
for the fiscal year ended December&nbsp;31, 2019, filed with the SEC on March&nbsp;26, 2020;</A></FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> Our Quarterly Report on Form&nbsp;10-Q for the fiscal quarter ended March&nbsp;31, 2020, filed on
<A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465920057436/tm2014426-1_10q.htm">May&nbsp;6, 2020;</A> </FONT></DD></DL>
</UL>
<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>13</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=4,SEQ=30,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=891945,FOLIO='13',FILE='DISK135:[20ZCT4.20ZCT40304]DC40304A.;6',USER='CHE105939',CD='12-JUN-2020;11:02' -->
<A NAME="page_dc40304_1_14"> </A>

<P style="font-family:times;"><FONT SIZE=2><A HREF="#bg40304a_main_toc">Table of Contents</A></FONT></P>

<UL>
<DL compact>
<DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2>  <A HREF="http://www.sec.gov/Archives/edgar/data/744218/000104746920002644/a2241464zdef14a.htm">Our Definitive Proxy Statement on
Schedule&nbsp;14A, filed with the SEC on April&nbsp;28, 2020 (other than the portions thereof which are furnished and not filed); and</A></FONT><FONT SIZE=2>
<BR><BR></FONT></DD><DT style='font-family:times;margin-bottom:-11pt;'><FONT SIZE=2>&#149;</FONT></DT><DD style="font-family:times;"><FONT SIZE=2> The description of our common stock contained in our Registration Statement on Form&nbsp;8-A, filed on
<A HREF="http://www.sec.gov/Archives/edgar/data/744218/000104746904033435/a2146123z8-a12g.htm">November&nbsp;8, 2004,</A> as amended by Form&nbsp;8-A/A filed on
<A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465907076169/a07-27173_78a12ga.htm">October&nbsp;22, 2007</A> and
<A HREF="http://www.sec.gov/Archives/edgar/data/744218/000110465908016208/a08-7663_18a12ga.htm">March&nbsp;7, 2008</A>. </FONT></DD></DL>
</UL>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
also incorporate by reference all documents we file under Sections&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act (a)&nbsp;after the initial filing date of the registration
statement of which this prospectus is a part and before the effectiveness of the registration statement and (b)&nbsp;after the effectiveness of the registration statement and before the filing of a
post-effective amendment that indicates that the securities offered by this prospectus have been sold or that deregisters the securities covered by this prospectus then remaining unsold. The most
recent information that we file with the SEC automatically updates and supersedes older information. The information contained in any such filing will be deemed to be a part of this prospectus,
commencing on the date on which the document is filed. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nothing
in this prospectus shall be deemed to incorporate information furnished but not filed with the SEC pursuant to Item&nbsp;2.02 or 7.01 of Form&nbsp;8-K. </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;We
will furnish without charge to each person, including any beneficial owner, to whom this prospectus is delivered, upon written or oral request, a copy of any documents incorporated by
reference other than exhibits to those documents. Requests should be addressed to: </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>Corporate
Secretary<BR>
Celldex Therapeutics,&nbsp;Inc.<BR>
Perryville III Building, 53 Frontage Road, Suite&nbsp;220,<BR>
Hampton, New Jersey 08827<BR>
(908)&nbsp;200-7500 </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2>14</FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=5,SEQ=31,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=232061,FOLIO='14',FILE='DISK135:[20ZCT4.20ZCT40304]DC40304A.;6',USER='CHE105939',CD='12-JUN-2020;11:02' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->

<P style="font-family:times;"><FONT SIZE=2>

<!-- COMMAND=ADD_BASECOLOR,"#000000" -->




<!-- COMMAND=ADD_DEFAULTFONT,"font-family:times;" -->




<!-- COMMAND=ADD_TABLESHADECOLOR,"#CCEEFF" -->




<!-- COMMAND=ADD_STABLERULES,"border-bottom:solid #000000 1.0pt;" -->




<!-- COMMAND=ADD_DTABLERULES,"border-bottom:double #000000 2.25pt;" -->





<!-- COMMAND=ADD_SCRTABLERULES,"border-bottom:solid #000000 1.0pt;margin-bottom:0pt;" -->




<!-- COMMAND=ADD_DCRTABLERULES,"border-bottom:double #000000 2.25pt;margin-bottom:0pt;" -->


</FONT> <FONT SIZE=2><A HREF="#bg40303a_main_toc">Table of Contents</A> </FONT></P>

<P style="font-family:times;"><FONT SIZE=2>&nbsp;<BR></FONT></P>


<P style="font-family:times;"><FONT SIZE=2><div
style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div> </FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>
<IMG SRC="g306206.jpg" ALT="LOGO" WIDTH="210" HEIGHT="51">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=5><B>Celldex Therapeutics,&nbsp;Inc.  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><B>Up to $75,000,000<BR>
Common Stock  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=4><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


 </I></FONT><FONT SIZE=4><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>PROSPECTUS SUPPLEMENT  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><I>

<!-- COMMAND=ADD_LINERULETXT,NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" -->
<HR NOSHADE  COLOR="#000000" SIZE="1.0PT" WIDTH="26%" ALIGN="CENTER" >


  </I></FONT><FONT SIZE=3><B>

<!-- COMMAND=ADDING_LINEBREAK -->

<BR>  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=3><B>
<IMG SRC="g561532.jpg" ALT="LOGO" WIDTH="231" HEIGHT="43">
  </B></FONT></P>

<P ALIGN="CENTER" style="font-family:times;"><FONT SIZE=2><B>June&nbsp;12, 2020  </B></FONT></P>

<P style="font-family:times;"><FONT SIZE=2><B> <div style="width:100%;border-top:solid #000000 1.0pt;padding:0in 0in 0in 0in;font-size:3.0pt;"></div>
<div style="width:100%;border-top:solid #000000 3.0pt;padding:0in 0in 0in 0in;font-size:4.0pt;"></div>  </B></FONT></P>

<HR NOSHADE>
<P style='font-family:times;page-break-before:always'></p>
<!-- ZEQ.=1,SEQ=32,EFW="2241865",CP="CELLDEX THERAPEUTICS, INC.",DN="1",CHK=403702,FOLIO='blank',FILE='DISK133:[20ZCT3.20ZCT40303]HO40303A.;11',USER='JTAYLORA',CD='12-JUN-2020;13:28' -->
<!-- THIS IS THE END OF A COMPOSITION COMPONENT -->
<BR>
<!-- TOCEXISTFLAG -->
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g985367.jpg
<DESCRIPTION>G985367.JPG
<TEXT>
begin 644 g985367.jpg
M_]C_X  02D9)1@ ! 0$!&P$;  #__@!%35),3%]'4D%02$E#4SI;0T5,3$1%
M6%]42$5205!%551)0U-=0T5,3$1%6%]42$5205!%551)0U-?0U],3T=/+D50
M4__; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_  !$( "D JP,!(@ "$0$#$0'_Q  >   " P " P$            )
M"@ '" 0& 0(#"__$ #T0  $$ P ! P$& @8(!P    4" P0& 0<("0 1%!(*
M$Q46(3%!@2(C)&&QMQ<8&CA1<7>1.6)R=H*RPO_$ !P!  $$ P$
M      4#! 8'  $""/_$ "@1  (#  $$ @(" @,       ,$ 0(%!@<1$A,
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MK>@15[CCQ#19K/3)=9D;.(QYW96&0@S9YO8"E2KDK85W=:<DZI[%U;,UKLV
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9[TJ+/'=623K9[U0 82,>I-*EG+#7J.?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g561532.jpg
<DESCRIPTION>G561532.JPG
<TEXT>
begin 644 g561532.jpg
M_]C_X  02D9)1@ ! 0$!L &P  #__@!!35),3%]'4D%02$E#4SI;4D]#2U=%
M3$Q?345$24-!3%]414-(3D],3T=)15-=0T%.5$]27S1#7TQ/1T\N15!3_]L
M0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_\  $0@ *P#G P$B  (1 0,1 ?_$ !X   (" P$! 0$           H+" D
M!@<%! ,"_\0 0!    <  0,# @,$!@<)     0(#! 4&!P@)$1( $R$*,105
M(AE!6&$7,E%QE],6&"-R@9C6)"4F,Y&BU-7A_\0 & $! 0$! 0
M    !P@&!03_Q  P$0 " @$#! (! @8!!0     " P$$!081$@ '$R$4(C$C
M00@5%C(S420T0E)A@__:  P# 0 "$0,1 #\ /MD)!C%,7DG)O&L?'1[5P^?O
MWSA%HR9,FB)W#IV[=.#IMVS5LW347<.%U$T4$4U%EE")D,8 U>I9]3!,QUCL
M>.=/-I +1\2N_A9CDU;8E&PMY.0;K?ASNL8I[TWY.ZB6JB2OX.\W9I+,)SW"
MN82I'C",YN0W3ZF_J*SM/C*YT_\ )Y\8Y>]5QG?>1DI$OE$Y+_0Q\[53I.5+
MG0\3-&5O49.K5;FPJ$<2%>95^)7*:&L4BB\"C33464(DDFJLJJ<B:22*9UEE
ME5# 1-%%%,#**K*J&*DBBF4RBJIB)IE,<Q0&F^T7:C'9#'HU5J>N-M5F99B<
M6[_II0!2,7KH;QYX<0E\>N<>#PQ#FBZ'+%4Z]T^YUZC>;IG3;RKN1Q#)9%,Q
M+X><044ZA1$RHEP0^9P3Y?+/B"5^,Y9VW=N2W(#D[9V]RY";#?=ALK)!5I'2
M=YFSR@Q+-90%5F4,Q22:Q4*R44*4YV<2P9-C&*012$2%[:5FVHZ3CEMC[[DU
M]MV:W:**LG&VRD3S^N6!DDY*4KA)O)QJR+@B+@I"%70$QD5BE*55,X  >C4.
MGQ],]@Y,9J]_YVA>;AK=X@F$Z\R:O6R5H-7RIO*-TWC6MRLC5UVMDM-U8(*(
MEL;T\RRKT=)'=0\;$OB,?SM_4_UV^D-D73M:Y+LO'ZQV,F3:G:);/YBCWN?2
MGI.G7-C KV:)<UVQND6TI+UV>AXR<*[939GDA!R<:W%&3>LI<C:,4,/W+T%D
M\R.B\8N>!DZG5D,>A>#M$L3-E>O E[!G%G CJK0Z8^AGY DS?*]NM;8_%%J[
M(%$L&%7+ S;:>71!D @]VX_WAR7)"#S<J-X,!\9<92]*?ZBO7X'2*?A7/BS-
M]$S6X2,358'?W<=%P]XSF6>J)1L0XT=2'9Q\7=*6Z>*-FTQ95F+.V5OWE)R2
M?62.3=HLCCRF P (#W 0[A^_[_S#N @/W 0$0$/D!$! ?29GWV2O=(SQEXK
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M6+,ZXO0*9>,U5U\34I$3%1$A(^,624?>8V*>MC^[VDTWUX2:>H*93;^'+,@
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MVB/<1'X^1[_ =@_X 'P ?R]'P?571\POP<PN1:N#DA8_E37TY=J4RX$7</\
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MEIK''ZY*Q"ZZC1"ZT>7,Y?9[IL&V4$1@;U74UTDGY")*+DB9YF9K9JRNL9W
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M,S&^WE0L_6WL1_UTJZQ*AJZKL^09>V*59QI&J9S04DB@945#7&YPE=,3VDC
MH<!3D3B8I! PD W8Q?ZP.!VK1NT9H,6J"39HU13:-FR9?%%%LV("#=$A ^ 2
M(BF1,"!\> >/V]18K7 K@_3+%!6^H\/^,M7M57EV$_6[) 8;FL1.P$Y%.4WD
M9,0TJPK:#Z-E(YVDDZ8OV:Z+IJX3(L@J10A3!++T3]S^XB-?V,.=6A8QZ,6F
MX,KL.6V6-MFB3,?'$",0%98^]YF=_P!ND_MQH-^AZ^4"S=KW79%U8_)74Q<
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M*BI9]#M'LJ,JY#-B>ZLF@<5IV<,B:/K43+R:B34Q?74?XOYQTJ^@]=>-F=O
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LR$#O$3O$;K3^*C!X7'X@2$QH(BN)COL8B92)3O [$0S$G&T1!R6V\;3/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g306206.jpg
<DESCRIPTION>G306206.JPG
<TEXT>
begin 644 g306206.jpg
M_]C_X  02D9)1@ ! 0$!6P%;  #__@!%35),3%]'4D%02$E#4SI;0T5,3$1%
M6%]42$5205!%551)0U-=0T5,3$1%6%]42$5205!%551)0U-?0U],3T=/+D50
M4__; $,  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! ?_; $,! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! ?_  !$( #( T@,!(@ "$0$#$0'_Q  ?   " @(" P$
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M7A N,)TWI\7XSPJSS+EJJ!::>,Y6;K96%;=$4QNZ)O$1<WP-CD56K62EF!3
M24'+3$#B G4;ZHUIVI=26(\/+2E+UQ9+^[." 5S$V/+@-_+\MW;&OB*K%TQ)
M9(JT+2C 11V!49&U%.X!I#1,Y/9^\LR3F-V#P@_<N5XN'>5'*5<;F 3-V"]B
M"0JUK(4X]_+]]7A*X\*B'8#+ ]7 /$HIQ9SC!?L_%8D'.7MB;F1%Q\+A\;4J
MK*K@H<K09&PVN3F$T%$@+X%7)&=:4514$Y3MTU%@*4Y71A)A/C^G?T.54[5A
MQ,:XGK,8[A8(FNXOB6'<P"ES$&(_G]0^93)R1S2?M;S'DO*/>OC^SJ7FW+N@
MS2JO ?(:R,V<K0;-*M7B2%%*M("Y:H[_ *9</<;'DQQZ.]H&</\ 7#J4],W=
MN0:@G2*J_J\;.2;5H=58AL-YF8WR?9O5?"= QG-(OTFM%MQ*5PHG'RQB"<$@
M,BW[#RT;/14=-PS]G*0\NQ:2D5)1ZZ3IC(1D@W3>1SYFY1,=%PT>,ET'+99(
MQDU452*$,)3 /(1=1G1/'_4,UCM>!+F["OS@.F]NQ??$VOOKJ@9*A6SQ&!L'
MN8'3&2B'+=\_@K1#BH096MRLDV;JMI K!ZU6UUZZCN]/14CX[5#J*ZW9!RA@
M"D+'@<1YTH*I90(RIM%$DX^%J]TER,Z9?Z8Q9@!Z[7;3-TG(M,9N$X*037C&
M<9&1VR54)]Q.&\<S\9M<^6\/7?S68K[":UK:Q;5HKU.UE2\UKLNH&U]>Q3%D
MOD)AP#^0!FO&7(X5R?;NZ:W!QSDIU+P:JDM>C,TZ]<:MBOH0D3-*K0@#DV)#
MXX+L"GH3);G'-+[&9LK6M^!\OYYMZB!:[B3'=LOLBBX=>YED/HY#.G[.'1<
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MB$A.6^95>'20!M-+1R;:2,,>"$FJU30?F<%,3W'RG9BI/#+D$Y?=1*KYA1,
MIF 1YK-G@3 \5(LY%AAS$L;*MW(.V#]ICJDLY!!XF(J Y:.D81)TDY()C'!9
M Y52B(F\0"(CRC7J(P0.]N[$\V*&K)8><:UQ$;A20R;AC,&9J*E<5I&8');7
M';7$-MJ(5'-2B@1+N+F+$HY?.HPD8G%J,4D4#G^WM"]MP[0>D'F'-LGDQ]6,
M0V2[,LJWBXTB>3N->B[OC"8B<?O<C5BNN[K(Q#HK)O%Q$B9])2;Y!X5-22.$
M@=VBDM'D5BNZ\D%L0E#%K<8W(7,K*VBJ;;*1B"2N%O.RDC\@;7692:QGOTYO
M]PA_B>Y5M<>4-; N5D'<L:5:'(KLWLO'LWM"F5<FYE;X+SMJBYA,1=S:+7&Z
MJ)08W@WJ\UC&M'N60K2],RJU!KDW:K,[:MUY%PRAJ[&N)63428LBK.W2Z+)L
MJ=%BV2.Z7.!46Z)U#D(.II?/=.88WQ1E^GT6_P"2*WF*;QXRKA\>4P)&<CHG
M*!".X^Z6F->+Q;V#JL2U<)O;8_=>)Y#I*_UABJL!R%J'Q/6X+8W6GJYO6],G
M[=%W?/&9,@8PAIVL6.*FY26C\70$_CR7B:Y+-HZ:+(DFF4=)PC([0K@[KW5-
M1F*QS->>AF&F/3].;05KAN&=,DF6W>I1,BLHVO6J'=HY2:RR1,IN9AA+,&LB
M#D+*#H9E^"/P91P"BC=<R  /$Q;+R@F*6H4%0?95,-DFL8FY->?")5"S7*_%
MDS^X_(/?<3$RF?[@Z3ELMU:5!6>SC&CKT2BV;;S[=#D!9,_6@Z?UGU3JPFT<
MC!&G[*NX() C83>2<='F;D?OF;([Q<K9H5VZ0;&=.##V(@V*NHF+A8XB'A21
M ZANX=B^H<QDWL6P:&<2[MBR9 8A#KR2[9LU YC!Y93JNSD1 QC@'@*8WB$P
M!X0$0]%^-IFN"6>T>YJ^\N.,B9 -8<;8Y9Z;-:W6[M857M>1JSAO8X7"4K",
M9&%IF7%,F';J.I=U\/?-W*B+HZRL.=PD[^AWQJD$M4=%7N3?I75"U7'L\V/&
M[+XNG]E,$J3+VF5=F:K;&+XVE(J=8Y<30;'+7KO%U^1;.IE"><)KLUT"+*^V
M;1@%TQKI*:C(7\96OC9$?<FIYV?-(KKP8Q]E$2PY<F1F/'N"E=;]Q'HK\C<&
M50:6';BK%5FU-:R _P"4!X<OV?LYRJ>0%A*YU\X#N6#OT""1^.#%I7SD9QRI
M"*)MFBB:A2G(H1N@<AR' #%.0Y4Q*<IBB E,41*8! 0$0'OPXFW"90RC'0L1
M'U[038^6@&$7'LH.5I.?-V(>FR4.U:)(1DA4HERZ%S%UAXR(@Y@8YP(KLHI1
MHV5$5$C<.-T<MK]1W6F)ZCOI>H41/Z>^BC(Z*(_E,?B?&)C]X]1(/?/-D1DL
M28*1&2@$<O8$3,#WXL'@DBP8F9\3&?$HCRC\3Z<SY@<1 /0>WK_]X<.3#U?W
MKH.8P!Z&$/7[Q_/S/N/WC^T>'#AZ/7?PX<.'H]'#APX>CT<.'#AZ/1PX<.'H
M]',%!$"AV$0^L7Y>GV\.'#T>N0_L_P"$?_7G _BB/V@(]A_\NW\/3APX>CUP
M7\4P_;Z^OV_+[^<B(^#OW]>P>O[.'#AZ/7641$WJ(C]8/F(_<'*R.D0(_P#!
M=7P[CV_"YL"';OZ=OPRV\>WZ.XCZ?G'[^'#C:[_6U#_P.G_ZV7ZB&A_MUQ?_
M ):YG_[APKU9TH(@)>PB'<#=^WYA+V_9W']H\#>A2B'H/IZ_I#N/[1^?#AQR
M]2_UR41\)O4?M_AS$HB)2]Q'\8/M_-PX</1ZY.(@/H(AZ?9^O@H(AX.PB'J/
5R]/LX<.'H]8=Q^\?VCPX<.'H]?_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
